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ABSTRACT OF DISSERTATION

THE ROLE OF THE NR4A ORPHAN NUCLEAR RECEPTOR NOR1 IN VASCULAR
CELLS AND ATHEROSCLEROSIS

The neuron-derived orphan receptor 1 (NOR1) belongs to the NR4A nuclear
receptor subfamily. As an immediate early response gene, NOR1 is rapidly induced by a
broad spectrum of physiological and pathological signals. Functional studies demonstrate
NOR1 as a constitutively active ligand-independent nuclear receptor whose
transcriptional activity is dependent on both expression level and posttranslational
modifications. To date, an increasing number of studies have demonstrated a pivotal role
of NOR1 in the transcriptional control of metabolism and the development of
cardiovascular diseases.
In this dissertation, we demonstrate NOR1 expression in endothelial cells and
sub-endothelial cells of human atherosclerotic lesions. In response to inflammatory
stimuli, NOR1 expression is rapidly induced in endothelial cells through an
NF-κB-dependent signaling pathway. Functional studies reveal that NOR1 increases
monocyte adhesion by inducing the expression of adhesion molecules VCAM-1 and
ICAM-1 in endothelial cells. Transient transfection and chromatin immunoprecipitation
assays identify VCAM-1 as a bona fide NOR1 target gene in endothelial cells. Finally,
we demonstrate that NOR1-deficiency reduces hypercholesterolemia-induced
atherosclerosis formation in apoE-/- mice by decreasing the macrophage content of the
lesion.
In smooth muscle cells (SMC), NOR1 was previously established as a cAMP
response element binding protein (CREB) target gene in response to platelet-derived
growth factor (PDGF) stimulation. CREB phosphorylation and subsequent binding of
phosphorylated CREB to the NOR1 promoter play a critical role in inducing NOR1
expression. In this dissertation, we further demonstrate that histone deacetylase (HDAC)
inhibition potentiates and sustains PDGF-induced NOR1 mRNA and protein expression

in SMC. This augmented NOR1 expression is associated with increased phosphorylation
of CREB, recruitment of phosphorylated CREB to the NOR1 promoter, and
trans-activation of the NOR1 promoter. Additionally, HDAC inhibition also increases
NOR1 protein half-life in SMC.
Collectively, these findings identify a novel pathway in endothelial cells underlying
monocyte adhesion and expand our knowledge of the epigenetic mechanisms
orchestrating NOR1 expression in SMC. Finally, we establish a previously unrecognized
atherogenic role of NOR1 in positively regulating monocyte recruitment to the vascular
wall.
KEYWORDS: nuclear receptor; endothelial cells; atherosclerosis; smooth muscle cells;
epigenetic mechanism

Yue Zhao
Student’s Signature
March 23, 2011
Date

THE ROLE OF THE NR4A ORPHAN NUCLEAR RECEPTOR NOR1 IN VASCULAR
CELLS AND ATHEROSCLEROSIS

By
Yue Zhao

Dennis Bruemmer
Director of Dissertation
Geza Bruckner
Director of Graduate Studies
March 25, 2011
Date

RULES FOR THE USE OF DISSERTATIONS

Unpublished dissertations submitted for the Doctor's degree and deposited in the
University of Kentucky Library are as a rule open for inspection, but are to be used only
with due regard to the rights of the authors. Bibliographical references may be noted, but
quotations or summaries of parts may be published only with the permission of the author,
and with the usual scholarly acknowledgments.
Extensive copying or publication of the dissertation in whole or in part also requires the
consent of the Dean of the Graduate School of the University of Kentucky.
A library that borrows this dissertation for use by its patrons is expected to secure the
signature of each user.
Name

Date

DISSERTATION

Yue Zhao

The Graduate School
University of Kentucky
2011

THE ROLE OF THE NR4A ORPHAN NUCLEAR RECEPTOR NOR1 IN VASCULAR
CELLS AND ATHEROSCLEROSIS

DISSERTATION
A dissertation submitted in partial fulfillment of the
requirements for the degree of Doctor of Philosophy in the
College of Medicine, Graduate Center for Nutritional Sciences
at the University of Kentucky

By
Yue Zhao
Lexington, Kentucky
Director: Dr. Dennis Bruemmer, Professor of Endocrinology and Molecular Medicine
Lexington, Kentucky
2011
Copyright © Yue Zhao 2011

ACKNOWLEDGEMENTS
This dissertation would not have been possible without the support of several
individuals who have contributed their valuable assistance to the completion of my study.

First and foremost, I would like to show my sincerest gratitude to my supervisor, Dr.
Dennis Bruemmer, for standing by my side throughout my doctoral study with his
knowledge and patience. It was he who led me into the world of science and helped me
grow into an independent researcher. He provided me with many opportunities to attend
and present my work in conferences and encouraged me to meet other scientists. I
attribute the level of my Ph.D. degree to his guidance and effort.
I would also like to express my gratitude to the other committee members, Dr.
Bernhard Hennig, Dr. Michael Kilgore, and Dr. Michal Toborek, for their valuable
expertise and insights regarding the relevance of my study to a broader field. I also would
like to thank my outside examiner, Dr. Sidney Whiteheart, who was willing to attend my
dissertation defense.
I want to acknowledge Dr. Lisa Cassis and Dr. Geza Bruckner for offering me the
opportunity to study in the Graduate Center for Nutritional Sciences.
Also, I want to thank Dr. Alan Daugherty for his expertise in the area of
atherosclerosis and for helping with atherosclerosis analysis in my study.
I would like to thank my former and current co-workers: Takashi Nomiyama,
iii

Elizabeth B. Heywood, Karrie Jones, Florence Gizard, Dianne Cohn, Hannes Findeisen
and Hua Qing. They have made a great contribution to my doctoral study, sharing
scientific ideas and helping me with experiments. They have also been a great help in my
personal life by making it easier and happier. It was a wonderful experience for me to
work with them.
I would like to thank the organizations that provided funding for these projects:
N.I.H., Kentucky Opportunity Fellowship, AHA Pre-doctoral Fellowship, and University
of Kentucky Dissertation Year Fellowship.
Finally, I owe my deepest gratitude to my parents and my husband for their love
and constant support during my study. I also want to thank my dear friends for sharing
fun times with me.

iv

TABLE OF CONTENTS
Acknowledgements ............................................................................................................ iii
Table of contents ..................................................................................................................v
List of tables ...................................................................................................................... vii
List of figures ................................................................................................................... viii
List of files ...........................................................................................................................x
Chapter one: Introduction ....................................................................................................1
1.1. Background .............................................................................................................. 1
1.1.1. Introduction on atherosclerosis .......................................................................... 1
1.1.2. Introduction on epigenetics ............................................................................... 4
1.1.3. Introduction on NR4A orphan nuclear receptors .............................................. 5
1.1.3.1. Molecular biology of NR4A orphan nuclear receptors .................. 6
1.1.3.2. NR4A nuclear receptors in metabolism and energy balance ......... 8
1.1.3.3. NR4A nuclear receptors in vascular biology ............................... 11
1.2. General hypothesis and specific aims .................................................................... 15
Chapter two: Deficiency of the NR4A orphan nuclear receptor NOR1 decreases monocyte
adhesion and atherosclerosis ..............................................................................................21
2.1. Synopsis ................................................................................................................. 21
2.2. Introduction ............................................................................................................ 22
2.3. Material and Methods............................................................................................. 23
2.4. Results .................................................................................................................... 29
2.5. Discussion .............................................................................................................. 34
Chapter three: Epigenetic regulation of the NR4A orphan nuclear receptor NOR1 by
histone deacetylase inhibition ............................................................................................68
3.1. Synopsis ................................................................................................................. 68
3.2. Introduction ............................................................................................................ 69

v

3.3. Materials and Methods ........................................................................................... 71
3.4. Results .................................................................................................................... 74
3.5. Discussion .............................................................................................................. 76
Chapter four: General discussion .......................................................................................91
4.1. Discussion .............................................................................................................. 91
4.1.1. Summary.......................................................................................................... 91
4.1.2. The role of NOR1 in endothelial cells ............................................................. 92
4.1.3. The role of NOR1 in vascular smooth muscle cells ........................................ 94
4.1.4. The role of NOR1 in atherosclerosis development ......................................... 96
4.1.5. Implications for the prevention of cardiovascular diseases ............................. 98
4.2. Perspectives .......................................................................................................... 100
4.3. Conclusion............................................................................................................ 101
Appendices.......................................................................................................................108
Appendix A. Methods ................................................................................................. 108
Appendix B. Additional data ....................................................................................... 118
References ........................................................................................................................120
Vita...................................................................................................................................139

vi

LIST OF TABLES
Table 1.1. NR4A orphan nuclear receptors are induced by pleiotropic physiological and
pathological signals................................................................................................... 16
Table 2.1. Oligonucleotides used in this study ................................................................. 38

vii

LIST OF FIGURES
Figure 1.1. Molecular biology of NR4A orphan nuclear receptors ...................................18
Figure 1.2. NR4A receptor function in metabolism and energy balance ...........................19
Figure 1.3. Expression and function of NR4A receptors in vascular cells ........................20
Figure 2.1. NOR1 is present in endothelial cells of human coronary atherosclerotic lesions
....................................................................................................................................40
Figure 2.2. NOR1 is induced by inflammatory stimuli in endothelial cells ......................45
Figure 2.3. NOR1 expression in endothelial cells is mediated through NF-κB-dependent
signaling pathways .....................................................................................................49
Figure 2.4. NOR1 induces VCAM-1 and ICAM-1 expression in endothelial cells ..........51
Figure 2.5. NOR1 is required for VCAM-1 and ICAM-1 expression in endothelial cells 55
Figure 2.6. NOR1 trans-activates the VCAM-1 promoter by binding to an NBRE
consensus site .............................................................................................................57
Figure 2.7. NOR1 mediates monocyte adhesion by regulating VCAM-1 and ICAM-1
expression ..................................................................................................................61
Figure 2.8. NOR1 deficiency decreases atherosclerosis in apoE-/- mice ..........................66
Figure 2.9. The expression of NR4A nuclear receptors in mouse aortic arteries in response
to high-fat diet feeding ...............................................................................................67
Figure 3.1. NOR1 expression is enhanced by HDACi Scriptaid in VSMC.......................82
Figure 3.2. siRNA-mediated knockdown of HDAC3 expression increases PDGF-induced
NOR1 mRNA expression...........................................................................................84
Figure 3.3. Scriptaid increases NOR1 promoter activity without affecting NOR1 transcript
stability.......................................................................................................................86
Figure 3.4. Scriptaid enhances CREB phosphorylation and the recruitment of
phospho-CREB to its binding sites in the NOR1 promoter .......................................88
Figure 3.5. HDAC inhibitor Scriptaid increases NOR1 protein stability ..........................90

viii

Figure 4.1. NOR1 increases NF-κB-dependent transcription activation by interacting with
NF-κB p65 without affecting p65 translocation ......................................................104
Figure 4.2. HDAC inhibition increases smooth muscle cell apoptosis............................105
Figure 4.3. NOR1 deficiency increases leukocytosis and leukocyte apoptosis in the
peritoneal cavity .......................................................................................................107

ix

LIST OF FILES
YueZhaoDissertation.pdf……………………………………………………Size: 3.28 MB

x

Chapter one: Introduction
1.1. Background
1.1.1. Introduction on atherosclerosis
Atherosclerosis is a chronic inflammatory and proliferative disease, in which immune
mechanisms interact with arterial risk factors to initiate early fatty streaks1, 2. Continued
lesion progression results in a mature lipid-enriched necrotic core surrounded by a cap of
activated smooth muscle cells1, 3. In this process, endothelial cells, smooth muscle cells
and monocyte-derived macrophages constitute the primary cell types responsible for
atherosclerosis development1, 2.
The endothelium, a barrier between circulating blood and tissues, does not support
leukocyte binding under normal conditions2, 4. However, at the early stage of
atherosclerosis, endothelial cells undergo inflammatory activation/dysfunction in response
to atherogenic factors, such as inflammatory cytokines and hypercholesterolemia5, 6.
Increased expression of chemokines and adhesion molecules leads to monocyte
recruitment into the arterial wall, which is the key initial step for atherosclerotic lesion
formation1. Numerous studies revealed that monocyte homing is a tightly regulated
process, including initial rolling along the endothelium, triggering adhesion, strengthening
adhesion and finally transmigrating across the endothelium. Many chemokines and
adhesion molecules are involved in this process, including vascular cell adhesion
molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1), platelet endothelial
cell adhesion molecule-1 (PECAM-1), selectins and integrins7. In vivo mouse model
studies demonstrate that reduced expression of adhesion molecules or chemokines protects
against the development of atherosclerosis. For example, the deficiency of monocyte
chemoattractant protein-1 (MCP-1) reduces macrophage recruitment and atherosclerotic
lesion formation in low density lipoprotein receptor (LDLR)-deficient mice and human
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apolipoprotein (apo) B transgenic mice8, 9. Consistently, deletion of MCP-1 receptor CCR2
markedly decreases aortic macrophage accumulation and lesion formation in apoE
knockout mice10. While whole body VCAM-1 deficient mice are not viable, studies using
different knockdown strategies demonstrate a VCAM-1 gene dosage-dependent effect on
atherosclerosis development11, 12. In addition, ICAM-1 deficiency has been shown to
protect against atherosclerosis formation in apoE knockout mice13.
The continuous retention of atherogenic lipoproteins, recruitment of monocytes, and
lipid uptake by monocyte-derived macrophages promote fatty streak formation1, 2. The role
of macrophage accumulation in promoting lesion initiation and progression was initially
demonstrated by the observation that hypercholesterolemic mice become resistant to
atherosclerosis when they are bred to macrophage-deficient mice14. Recent advances in
this area demonstrate that monocytes are highly heterogeneous and each subtype plays
distinct

roles

in

atherosclerosis

development15.

CCR2+CX3CR1+Ly-6Chi

and

CCR2–CX3CR1++Ly-6Clo monocytes constitute two major subtypes, and data suggest that
these monocytes utilize different receptors to infiltrate into the vascular wall16. While
CCR2+ monocytes are more efficiently recruited into the sub-endothelial space, CCR2monocytes exhibit a higher potential in developing into plaque cells16. In addition to
monocytes, other leukocyte subsets have also been observed in atherosclerotic lesions at
various stages17, such as neutrophils18, mast cells19, dendritic cells20,

21

and T

lymphocytes17. Although mostly found in the arterial adventitia, B lymphocytes are
thought to confer a protective immunity during atherogenesis17.
Further lesion progression advances by continued macrophage accumulation and a
broad range of inflammatory responses1, 2. Recently, emerging evidence recapitulates the
concept of inflammation resolution, which was considered only as a passive process.
However, recent findings suggest that this process in fact represents a large number of
actively regulated anti-inflammatory responses22,
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. Inflammation resolution in

atherosclerotic lesions can be achieved through several steps, including prevention of
macrophage recruitment, promotion of anti-inflammatory cytokine expression, and
efficient efferocytosis (clearance of apoptotic inflammatory cells)22, 23.
The observation that increased macrophage apoptosis reduces early lesion formation
is indicative of effective clearance of apoptotic cells in early atherogenesis24. On the
contrary, another study demonstrates that phagocytosis of apoptotic cells is impaired in
advanced atherosclerotic lesions25. These findings point to a protective role of
efferocytosis in early atherogenesis. The maintenance of efficient efferocytosis in later
stages may provide a novel strategy to attenuate atherosclerosis progression. Given the
important role of macrophages in efferocytosis23, these findings elicit an interesting
concept that macrophages promote atherogenesis by producing inflammatory cytokines,
while play a protective role through the clearance of apoptotic cells. Some evidence has
implied that macrophage phenotype can be triggered to switch between classically (M1)
and alternatively (M2) activated macrophages26. An increasing number of studies suggest
that M2 macrophages are less inflammatory and have a greater phagocytic capacity27.
Therefore, future studies on monocyte/macrophage subtypes may explain the
discrepancies observed in macrophages.
Progression of early fatty streaks into complex atherosclerotic lesions is
accompanied by SMC activation, migration and proliferation1, 2. Vascular SMCs constitute
the major component of arteries and maintain a quiescent contractile phenotype in normal
physiological conditions. In atherosclerotic lesions, inflammatory cytokines and mitogens
trigger SMC migration into the arterial intima. Intimal SMCs undergo a phenotypic
transition which is associated with a higher proliferation rate and greater synthesis
capacity28. In addition, intimal SMCs take up lipids and secrete extracellular matrix
proteins1, 2. A key role of these intimal SMCs is to form a fibrous cap under the endothelial
cell layer, stabilizing lesions and preventing the necrotic lipid core from interacting with
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blood1, 2. However, the continuous proliferation of SMCs and formation of extracellular
matrix further promote lipoprotein retention and contribute to the narrowing of the vessel
lumen1, 2. Another element of advanced atheroma is increased secretion and activation of
matrix metalloproteinases (MMPs). MMPs function to degrade extracellular matrix,
ultimately resulting in a thinner and more fragile fibrous cap prone to rupture1-3. While
plaque rupture and thrombosis usually lead to acute cardiovascular diseases such as
myocardial infarction and stroke, massive SMC proliferation plays a major role in the
failure of occlusive vascular disease interventions, such as in-stent restenosis.29
1.1.2. Introduction on epigenetics
It was proposed by Conrad Waddington in the 1950s that “An epigenetic trait is a
stably heritable phenotype resulting from changes in a chromosome without alterations in
the DNA sequence”30. This original definition of epigenetics emphasizes the heritability of
a phenotype through cell divisions. Intensive studies have revealed that cellular responses
to physiological/pathological signals involve a large number of transient chromatin
modifications. In fact, these chromatin changes in response to environmental cues exactly
reflect the ability of a cell to remember its past state31. Therefore, a broader definition of
epigenetics has evolved to include these transient events happening to the chromosome.
Factors involved in epigenetic regulation include DNA methylation, histone
modifications, transcription factors, non-coding RNAs, nucleosome position, and 3D
organization of genes in the nucleus31, 32. There are a variety of histone post-translational
modifications (PTM) which can be categorized into histone lysine acetylation, methylation,
ubiquitinization and sumoylation, serine/threonine phosphorylation, arginine methylation
and proline isomerization33. DNA methylation and histone PTM are most well
characterized epigenetic markers, which can be read and translated into signals dictating
gene activation and repression33, 34. For instance, acetylation of histone H4 on lysine 16
(AcH4-K16) is associated with increased gene expression35 and has been shown to disrupt
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higher chromatin structure in nucleosomal arrays36. This example represents a direct
mechanism in which chromatin modifications activate gene transcription by increasing
DNA accessibility to transcription factors33. Another mechanism by which chromatin
modifications indirectly influence gene transcription involves the recruitment of chromatin
binding proteins33. For example, acetylated histone H3 and H4 peptides only function to
recruit other bromodomain-containing transcription co-activators whose acetyl-transferase
activity is required for gene activation37.
Both DNA methylation and histone PTM are reversible33. The addition and removal
of these chromatin modifications are carried out by specific enzymes33. For example,
histone acetyl-transferases (HAT) add acetyl-groups to lysine residues while histone
deacetylases (HDAC) remove the acetylation33, 38. Gcn5 N-acetyltransferases (GNAT) and
MYST HATs are the two predominant families of HAT. A number of transcription
co-activators such as p300/CBP possess intrinsic acetyl-transferase activity and are
categorized as HAT39. In addition, eighteen human HDACs have been identified with
different substrate selectivity38. Similarly, all other chromatin modification enzymes
consist of a large number of family members40, 41. Therefore, the timely and sequential
actions of various chromatin modification enzymes are essential for orchestrating gene
expression.
Cardiovascular disease, which involves dysregulated gene expression in the
cardiovascular system 116, is one of the leading causes of death in the world1-3. Since every
single cell in the body is subjected to epigenetic regulation, understanding the underlying
mechanisms will provide further insight on the development, physiology and disease of
cardiovascular system42.
1.1.3. Introduction on NR4A orphan nuclear receptors
This part is published, with Yue Zhao as first author, in two review articles
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“Arterioscler Thromb Vasc Biol. 2010 Aug;30:1535; Copyright © 2010 American Heart
Association” and “Drug Discov Today Dis Mech. 2009;6:e43; Copyright © 2009 Elsevier
Ltd.”.
1.1.3.1. Molecular biology of NR4A orphan nuclear receptors
Nuclear receptors (NR) share a common structure consisting of a ligand-independent
AF-1 transactivation domain in the N-terminal region, a highly conserved DNA-binding
domain (DBD) composed of two zinc fingers recognizing specific DNA sequences, and a
ligand-binding domain (LBD) that contains a ligand-dependent AF-2 transactivation
domain in its C-terminal portion (Figure 1.1A)43. NR4A receptors share this common NR
structure, and the three members reveal a high degree of homology in their genomic
structure and conservation of their DNA binding domain (degree of conservation > 90%)44.
However, several lines of evidence indicate that NR4A receptors may represent a distinct
group of transcription factors that do not function in a classical manner. Mutational
analysis indicated that NR4A receptors function as constitutively-active receptors whose
transcriptional activity is independent on the LBD45,

46

. Instead, their transcriptional

activity and co-activator recruitment appear to be dependent on the N-terminal AF-1
domain46-48, which constitutes a common distinction of ligand-independent transcriptional
activation by NR49, 50. This initial observation was supported by the finding that the LBD of
NR4A contains hydrophilic surfaces instead of the classical hydrophobic cleft that
mediates co-activator recruitment of other NR48. Finally, this unusual structure of the
NR4A LBD has been recently confirmed by X-ray crystallography demonstrating that the
Nurr1 LBD contains no cavity as a result of hydrophobic residues in the region normally
occupied by ligands51. Considering these observations, NR4A receptors are currently
thought to function as constitutively-active and ligand-independent receptors, whose
transcriptional activity is primarily dependent on the expression of the receptor and its
posttranslational modification.
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NR4A receptors are early immediate response genes, which are induced by a
pleiotropy of stimuli including growth factors, inflammatory stimuli, cytokines, peptide
hormones, and cellular stress (Table 1.1)52. Once their expression is induced, NR4A
receptors activate transcription by binding as monomers or homodimers to canonical DNA
target sites, the NGFI-B-responsive element (NBRE) consisting of an octanucleotide
AAAGGTCA motif (Figure 1.1B)53,

54

. NR4A homodimers preferentially bind to the

Nur-responsive element (NurRE), which constitutes an everted repeat of the NBRE-related
sequence (AAAT(G/A)(C/T)CA) found in the pro-opiomelanocortin (POMC) gene
promoter55. In addition, Nur77 and Nurr1 (but not NOR1) heterodimerize with RXR and
activate transcription through a DR-5 element in a 9-cis retinoic acid-dependent manner56,
57

. This heterodimerization of Nurr1 with RXR is isotype-specific since Nurr1 interacts

only with RXRα and RXRγ but not with RXRβ 58. Furthermore, different NR4A receptors
can form heterodimers to synergistically activate transcription59. While it was initially
thought that NR4A receptors only activate genes, a recent study has provided first evidence
that Nurr1 can also repress inflammatory gene promoters by recruiting co-repressor
complexes60.
In addition to the rapid expression as early response genes, the transcriptional activity
of NR4A receptors is regulated by posttranslational modification. All three NR4A
receptors are phosphorylated at serine residues in response to growth factor-dependent
activation of various kinases, including MAPK, PI3K, Akt, JNK, and RSK58, 61-64. For
example, Nur77 is phosphorylated at Ser-350 and Ser-354 within the DNA binding domain,
which inhibits the trans-activation activity65, 66. Furthermore, phosphorylation of Nur77 at
Ser-105 induces nuclear export of the Nur77/RXR heterodimer complex67, providing an
additional mechanism by which phosphorylation may inhibit the transcriptional activity of
Nur77. In addition to phosphorylation, all NR4A receptors contain sumoylation consensus
sites, and sumoylation of Nurr1 induces or inhibits the transcriptional activity in a
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sumoylation site-specific manner68. Although still in its infancy, these posttranslational
modifications regulate the transcriptional activity and may represent a major mode of the
control of gene expression by NR4A receptors.
1.1.3.2. NR4A nuclear receptors in metabolism and energy balance
Carbohydrate metabolism
All three NR4A receptors are potently induced in the liver in response to physiological
stimuli, including fasting and glucagon stimulation (Figure 1.2)69, 70. Furthermore, hepatic
NR4A receptor expression is increased in diabetic mice as a model of pathologic
gluconeogenesis69.

Functional

studies

further

demonstrated

that

adenoviral

over-expression of Nur77 increases the expression of genes involved in gluconeogenesis
and stimulates hepatic glucose production in mice69. Interestingly, Nur77 over-expression
induces several gluconeogenic genes including G6pc, Fbp1 and Fbp2, and enolase 3,
which all contain NBRE consensus sites in their promoters69. Therefore, this study has
provided the first experimental evidence that NR4A receptors regulate gluconeogenesis
and may serve to link hormonal stimulation to downstream metabolic gene expression.
In skeletal muscle, NR4A receptors are induced by growth factors, β-adrenergic
signaling, and endurance exercise71-74. Maxwell et al. first demonstrated that knock-down
of Nur77 in muscle cells results in decreased lipolysis and expression of genes regulating
energy expenditure and lipid homeostasis, including AMP-activated protein kinase, UCP3,
Glut4, CD36, adiponectin receptor 2, and caveolin-372. Conversely, Cao et al. reported that
overexpression of Nur77 in C2C12 muscle cells increases the expression of genes involved
in glucose and glycogen metabolism while Nur77 deficiency in mice reduces the
expression of genes involved in skeletal muscle glucose utilization in vivo75. Consistent
with this role of Nur77 to promote glucose utilization was the observation that
Nur77-deficient mice develop skeletal muscle insulin resistance when fed a high fat diet
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due to altered insulin signaling and reduced GLUT4 expression76. Although glucose
metabolism has not been studied in NOR1-deficient mice, knock-down of NOR1 in
skeletal muscle cells attenuates the expression of genes that control fatty acid oxidation and
pyruvate use (i.e. PGC-1α, PGC-1β, lipin-1α, PDP1r and PDP1c) indicating that NOR1
may be necessary for oxidative metabolism77. Finally, NOR1 has recently been
demonstrated to also promote insulin-stimulated glucose uptake in adipocytes by
augmenting insulin signaling and GLUT4 translocation78. In concert, these intriguing
observations point to a key role of NR4A receptors in the transcriptional control of glucose
homeostasis and oxidative metabolism.
Lipid metabolism
Accumulating evidence indicates that NR4A receptors regulate various aspects of
lipid metabolism. As noted earlier, initial experiments by Maxwell et al. demonstrated that
Nur77 promotes lipolysis in muscle72. Subsequently, Pols et al. revealed that Nur77
modulates plasma lipoprotein profiles and hepatic lipid metabolism in mice79. In this study,
adenoviral-mediated over-expression of Nur77 increased plasma LDL cholesterol and
decreased HDL cholesterol while reducing hepatic triglyceride levels, which was thought
to be due to a repression of the lipogenic transcription factor SREBP1c79. Consistent with
these data, Chao et al. noted hepatic steatosis and increased SREBP1c expression in
Nur77-deficient mice fed a high fat diet76. However, since Nur77 did not directly affect
SREBP1c activity in reporter assays, the authors concluded that the hepatic steatosis in
Nur77-deficient mice was likely secondary to the lipogenic effect of hyperinsulinemia76.
In 3T3-L1 preadipocytes, NR4A receptors expression is induced during adipogenesis
and initiating of the differentiation program80, 81. Initial studies using siRNA approaches
and over-expression of a Nur77 mutant lacking the N-terminal AF-1 trans-activation
domain indicated that Nur77 is not required for adipocyte differentiation82. However, a
functional role for NR4A receptors in adipogenesis was suggested by two recent in vitro
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studies, which have demonstrated that constitutive NR4A receptor expression in 3T3-L1
preadipocytes inhibits adipocyte differentiation83, 84. One of the mechanisms proposed for
this negative regulation of adipogenesis by NR4A receptors has been the inhibition of the
mitotic clonal expansion of preadipocytes83. However, considering that the initial mitotic
expansion step is primarily a prerequisite for 3T3-L1 preadipocyte differentiation, further
studies seem required and there are likely additional mechanisms involved by which NR4A
receptors inhibit adipogenesis. These may include a direct regulation of target genes
affecting adipogenesis, including extracellular matrix genes83. In addition, NR4A receptors
may cross-talk with adipogenic signalling and transcriptional programs, particularly since
Nurr1 and Nur77 have been reported to interact with Wnt signaling pathways or the
glucocorticoid receptor, which both play important roles in adipogenesis85-87.
Energy homeostasis
Brown adipose tissue plays a key role in energy balance and is the primary organ
involved in thermogenesis through uncoupling of mitochondrial respiration by the action
of uncoupling proteins (UCP). Early studies have demonstrated that Nur77 expression is
highly induced in response to β-adrenergic stimulation of brown adipocytes while
transcript levels of all three NR4A receptors are induced during cold-exposure88,

89

.

Kanzleiter et al. demonstrated a repressive effect of Nur77 on the UCP-1 promoter in
brown adipocytes, which was likely indirect since Nur77 did not directly interact with the
UCP-1 promoter88. Despite this repression of UCP-1, nonshivering thermogenesis was not
affected by Nurr77 deficiency in mice88. In contrast, Kumar et al. observed that NOR1
transcriptionally up-regulates UCP-1 expression by binding to an NBRE site on the UCP-1
promoter89. Furthermore, over-expression of a Nur77 mutant lacking the N-terminal AF-1
trans-activation domain prevented UCP-1 transcription induced by β-adrenergic
signaling89. The reasons underlying these seemingly conflicting two studies remain unclear
but are likely due to a differential regulation of UCP-1 by Nur77 and NOR1. Moreover,
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NR4A receptors may affect the central regulation of energy homeostasis since injection of
NOR1 siRNA into the third cerebral ventricle significantly suppresses food intake and
body weight in mice90. In concert, these intriguing studies characterize NR4A receptors as
important regulators of energy balance and food intake, although the underlying
mechanisms remain elusive and warrant further studies in gene-targeted mice.
1.1.3.3. NR4A nuclear receptors in vascular biology
An increasing number of studies have demonstrated that all three members of the
NR4A subfamily are expressed in the developing neointima and in advanced
atherosclerotic lesions91-97.

Moreover, accumulating evidence indicates that NR4A

receptors constitute important transcription factors in the control of vascular gene
expression and play critical roles in essentially all aspects of vascular remodeling,
including cell viability, proliferation, and inflammation (Figure 1.3). In the following
section, we will briefly summarize these studies pointing to a previously unrecognized
function of NR4A receptors in vascular biology.
Cell viability and proliferation
Endothelial cell injury followed by the expression of adhesion molecules and the
subsequent recruitment of circulating monocytes constitute critical events for the initiation
of atherosclerosis98. All three NR4A receptors are potently induced by a variety of
pro-atherogenic stimuli in endothelial cells, including atherogenic lipoproteins,
inflammatory cytokines, growth factors, and hypoxia (Figure 1.3)92,

99-105

. The

transcriptional mechanisms governing this inducible expression have been primarily
studied in the context of growth factor and hypoxia-induced NOR1 expression. While the
former mechanisms involve a cAMP response element binding protein (CREB)-dependent
activation of the NOR1 promoter101,

105

, NOR1 expression in response to hypoxia is

dependent on hypoxia-inducible factor 1 (HIF-1) binding to a hypoxia response element in
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the promoter103. Arkenbout et al. performed the first functional experiments in endothelial
cells and demonstrated that adenoviral over-expression of Nur77 inhibits proliferation of
this cell type by up-regulating p27Kip1 and down-regulating cyclin A92. However, the role
of Nur77 for endothelial cell proliferation remains controversial since Zeng et al. reported
that Nur77 induces proliferation and cell cycle gene expression102. Moreover, this report
noted that angiogenesis is induced by over-expression of Nur77 and decreased in Nur77-/mice102. With respect to the sibling NOR1, Rius et al. identified a mitogenic role for this
receptor by demonstrating that antisense oligonucleotides against NOR1 inhibit
endothelial cell growth and wound repair after injury101. Consistent with these
observations, NOR1 has recently been characterized as a pro-survival gene in endothelial
cells exposed to hypoxia by inducing the expression of cellular inhibitor of apoptosis
protein 2103. Collectively, these studies establish a role for Nur77 and NOR1 in regulating
endothelial cell survival and proliferation; however, little is known about the
transcriptional target genes and molecular mechanisms. At present, only two direct NR4A
target genes have been identified in endothelial cells. Gruber et al. characterized PAI-1 as a
Nur77 target gene, which is activated by the receptor through direct binding to an NBRE
site in the promoter99. In addition, You et al. demonstrated that Nur77 overexpression
prevents NF-κB nuclear translocation in endothelial cells by enhancing the expression of
IκBα, which is mediated through a direct trans-activation of a NBRE site in the IκBα
promoter104. Interestingly, the functional relevance of Nur77-dependent IκBα expression
was confirmed by the finding that Nur77 inhibited the expression of VCAM-1 and
ICAM-1 in endothelial cells104.
Similarly as in endothelial cells, NR4A receptor expression is rapidly induced in
response to atherogenic stimulation of smooth muscle cells (SMC), including lipoproteins,
cyclic stretch, and mitogenic stimuli91, 93-95, 106. The transcriptional induction of NOR1 in
SMC is mediated through mitogen-induced CREB binding to CRE sites in the NOR1
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promoter and can be pharmacologically inhibited by simvastatin93, 94, 106, 107. Consistent
with the earlier described growth-inhibitory function of Nur77 in endothelial cells, Nur77
over-expression inhibits SMC proliferation in vitro by stabilizing of p27Kip191,

108

and

reduces neointima formation in vivo91. Interestingly, data from the same group has further
recently suggested that SMC-specific over-expression of Nur77 inhibits pathological
outward remodeling in response to carotid artery ligation, which was associated with
decreased macrophage accumulation and MMP expression109. While these studies clearly
indicate that Nur77 prevents SMC proliferation, NOR1 has been reported to act mitogenic
suggesting a function that is distinct from that of Nur77. A proliferative role of NOR1 was
first reported by Martínez-González et al. using antisense NOR1 oligonucleotides93.
Consistent with these initial observations, data from our group has demonstrated a
proliferative defect and an increased propensity for apoptosis in SMC isolated from
NOR1-deficient mice94, 95. In vivo, the proliferative response and neointima formation
following endovascular femoral artery guide wire injury was decreased in NOR1-deficient
mice95. At a molecular level, this mitogenic activity of NOR1 was at least in part mediated
by a trans-activation of a canonical NBRE site in the cyclin D1 promoter, characterizing
cyclin D1 as a bona fide NOR1 target gene in SMC95. Furthermore, DNA microarray
profiling revealed a lower expression of NOR1 in elongated SMC while NOR1
knock-down suppressed DNA synthesis, further supporting the mitogenic function of
NOR1 and pointing to a potential role of NOR1 in regulating cell shape110. In concert, these
studies establish not only an important but also distinct role for Nur77 and NOR1 in the
control of vascular cell proliferation and remodeling. Continued investigation will be
required to define the transcriptional target genes and the molecular basis underlying the
differential function of NOR1 and Nur77 in SMC biology.
Inflammation
The first evidence linking NR4A expression with inflammatory signaling was
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reported by Woronicz et al. and Liu et al., who noted that Nur77 is induced in apoptotic
T-cells and that inhibition of Nur77 function prevented apoptosis111, 112. However, mice
deficient in Nur77 exhibit unimpaired T-cell apoptosis, and functional redundancy of
Nur77 and NOR1 in T-cell apoptosis has been suggested113, 114. Similarly to T-cells, Nur77
expression is increased in apoptotic macrophages and, in contrast to the experiments
performed in T-cells, peritoneal macrophages isolated from Nur77-deficient mice reveal a
phenotype of reduced cell death115. In response to inflammatory activation, all three NR4A
receptors are potently induced in macrophages96, 97. This inducible expression of NR4A
receptors in macrophages depends on the activation of NF-κB signaling, as exemplified by
the recruitment of NF-κB to response elements in the Nur77 promoter96. Functional studies
have indicated that NR4A receptors both activate and repress inflammatory genes in
macrophages60, 97, 116. An initial microarray analysis by Pei et al. discovered that NR4A
overexpression in macrophages induces proinflammatory gene expression116. Interestingly,
among the identified direct Nur77 target genes was the inducible kinase IKKi/IKKepsilon,
which functions as a NF-κB activating kinase, providing a potential mechanism for the
activation of inflammatory gene expression by Nur77 in macrophages116. In contrast to
these studies, Bonta et al. revealed that lentiviral over-expression of each NR4A member
reduces certain inflammatory genes (i.e. IL-1β, IL-6, IL-8, MIP1α and 1β and MCP-1) and
the uptake of oxidized LDL97. Finally, a recent study by Saijo et al. identified that Nurr1
transcriptionally represses the inflammatory genes TNFα, iNOS, and IL-1β in microglia
and the murine RAW264.7 cell line60. This trans-repression was mediated through a
Nurr1-dependent recruitment of the co-repressor for element-1-silencing transcription
factor (CoREST) complex to the target promoter and the subsequent clearance of NF-κB60.
While these studies indicate that NR4A receptors function as important transcriptional
regulators of inflammatory gene expression, further in vivo evidence using animal models
deficient for either of the NR4A receptors seems required, particularly with respect to the
development of atherosclerosis.
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1.2. General hypothesis and specific aims
In conclusion, emerging evidence indicates that NR4A nuclear receptors have
multifaceted, even contradictory, effects in vascular cells and macrophages. The induction
of NOR1 in endothelial cells and smooth muscle cells elicit a proliferative effect on cell
growth. Whereas accelerated endothelial cell growth benefits revascularization after
vascular injury, increased smooth muscle cell proliferation leads to intimal thickening and
ultimately vascular occlusion. Additionally, the role of NOR1 in endothelial cell activation
and inflammatory signaling still needs to be investigated. In macrophages, recent studies
indicate that NOR1 can be either pro- or anti-inflammatory dependent upon the choice of
target genes and specific assays. Therefore, it is intriguing and necessary to further explore
the functions of NOR1 in vascular cells and to identify the net effect of NOR1 on
atherosclerosis development.
At the beginning of this study, we found that NOR1 expression is induced by
inflammatory stimuli in endothelial cells and increases adhesion molecule expression. In
addition, it was reported by our group that mitogen induced NOR1 expression promotes
vascular smooth muscle cell proliferation. Based on these findings, it was hypothesized
that NOR1 plays an atherogenic role in atherosclerosis development. In order to test
this hypothesis, two specific aims were proposed:
Specific aim I. To investigate how transcriptional induction of NOR1 during
endothelial cell activation contributes to monocyte recruitment and atherosclerosis
development.
Specific aim II. To characterize the epigenetic regulation of NOR1 expression in
vascular smooth muscle cells.
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Table 1.1. NR4A orphan nuclear receptors are induced by pleiotropic physiological
and pathological signals*
Stimuli
NR4A1
(Nur77)

NR4A2
(Nurr1)

Expression
locations

Effects

parathyroid
hormone117
Palmitate,
oleate118
nerve growth
factor, membrane
depolarization119
antipsychotic
drugs: raclopride,
olanzapine120
9-cis retinoic
acid56

bone

bone metabolism

pancreatic
beta-cells
PC12 cells

beta-cell adaptation to
hyperlipidemia
neuron survival during
development

CA1 region of
the
hippocampus
human chorion
carcinoma
JEG-3 cells

T-cell receptor
activation114
deficiency of
Nur77 and
NOR1121, 122

thymocytes

antipsychotic drug
effects in the central
nervous system
crosstalk between
retinoid and growth
factor signaling
pathways
thymocyte apoptosis

hematopoietic
stem cells,
myeloid
progenitors

mixed
myelodysplastic/myelo
proliferative
neoplasms, acute
myeloid leukemia

Nurr1 deficiency

mouse embryo
midbrain
CA1 region of
the
hippocampus

midbrain dopaminergic
cell differentiation
antipsychotic drug
effects in the central
nervous system

bone

bone metabolism

human chorion
carcinoma
JEG-3 cells

crosstalk between
retinoid and growth
factor signaling
pathways

123

antipsychotic
drugs: clozapine;
fluphenazine;
haloperidol;
risperidone;120
parathyroid
hormone124
9-cis retinoic
acid56

16

Potential
partners

Retinoid X
Receptor
(RXR)

Retinoid X
Receptor
(RXR)

Table 1.1. NR4A orphan nuclear receptors are induced by pleiotropic physiological
and pathological signals* (continued)
Stimuli
NR4A2
(Nurr1)

normal Nurr1
expression125

NR4A3
(NOR1)

antipsychotic
drugs:
risperidone,
clozapine120
NOR1
deficiency126

parathyroid
hormone127

T-cell receptor
activation114
deficiency of
Nur77 and
NOR1121, 122

Expression
locations
hematopoietic
stem cells

hematopoietic stem cell
quiescence

CA3 region of
the
hippocampus

antipsychotic drug
effects in the central
nervous system

semicircular
canal during
early otic
development
osteoblasts

inner ear defect, partial
bidirectional circling
behavior

thymocytes
hematopoietic
stem cells,
myeloid
progenitors

Effects

Potential
partners

crosstalk between
parathyroid hormone
and steroid hormone
receptor signaling
pathways
thymocyte apoptosis
mixed
myelodysplastic/myelo
proliferative
neoplasms, acute
myeloid leukemia

* The induction of NR4A orphan nuclear receptors in the liver, muscle, adipose tissues, and
vascular cells is summarized in Figure 1.2 and Figure 1.3.
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Figure 1.1. Molecular biology of NR4A orphan nuclear receptors
(A) NR4A nuclear receptors share a conserved molecular structure consisting of an
N-terminal AF-1 domain, a central DNA-binding domain (DBD), and a C-terminal ligand
binding domain (LBD) and AF-2 domain. (B) NR4A receptors induce gene expression by
binding as monomers to the NBRE site and as homodimers or heterodimers to the NurRE
site in the promoter of their regulated target genes. NurREPOMC represents the binding
sequence demonstrated in the pro-opiomelanocortin (POMC) promoter, while NurRECON
represents the NurRE site comprising consensus NBRE sites. Nur77 and Nurr1, but not
NOR1, heterodimerize with RXR and bind to the direct repeats of nuclear receptor
binding motif separated by five nucleotides (DR5).
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Figure 1.2. NR4A receptor function in metabolism and energy balance
NR4A orphan nuclear receptors are potently induced by physiological and pathological
stimuli in the liver, muscle and adipose tissues. In these tissues, NR4A orphan receptors
function as transcriptional regulators of gene expression programs involved in the control
of glucose homeostasis, lipid metabolism, and energy expenditure (see text for details).
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Figure 1.3. Expression and function of NR4A receptors in vascular cells
NR4A orphan nuclear receptors are induced in vascular cells by a variety of stimuli,
including inflammatory mediators, cytokines, hypoxia, and growth factors. In response to
these pathophysiological environmental cues, NR4A receptors modulate gene expression
leading to cell-specific processes (see text for details).

Copyright © Yue Zhao 2011
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Chapter two: Deficiency of the NR4A orphan nuclear receptor NOR1 decreases
monocyte adhesion and atherosclerosis
This part is published in “Circ Res. 2010 Aug;107:501; Copyright © 2010 American
Heart Association”, with Yue Zhao as first author.
2.1. Synopsis
The orphan nuclear receptor NOR1 is a member of the evolutionary highly conserved
and ligand-independent NR4A subfamily of the nuclear hormone receptor superfamily.
Members of this subfamily have been characterized as early response genes regulating
essential biological processes including inflammation and proliferation; however the role
of NOR1 in atherosclerosis remains unknown. In the present study, we demonstrate
expression of NOR1 in endothelial cells of human atherosclerotic lesions. In response to
inflammatory stimuli, NOR1 expression is rapidly induced in endothelial cells through a
NF-κB-dependent trans-activation of the NOR1 promoter. Over-expression of NOR1 in
human endothelial cells increased the expression of VCAM-1 and ICAM-1 while NOR1
deficiency altered adhesion molecule expression in response to inflammatory stimuli.
Transient transfection experiments and chromatin immunoprecipitation assays revealed
that NOR1 induces VCAM-1 promoter activity by binding to a canonical response element
for NR4A receptors in the VCAM-1 promoter. Further functional studies confirmed that
NOR1 mediates monocyte adhesion by inducing VCAM-1 and ICAM-1 expression in
endothelial

cells.

Finally,

we

demonstrate

that

NOR1-deficiency

reduces

hypercholesterolemia-induced atherosclerosis formation in apoE-/- mice by decreasing the
macrophage content of the lesion. In concert, these studies identify a novel pathway
underlying monocyte adhesion and establish that NOR1 serves a previously unrecognized
atherogenic role in mice by positively regulating monocyte recruitment to the vascular
wall.
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2.2. Introduction
The transcription factor NOR1 (NR4A3) belongs to the highly conserved NR4A
subfamily of orphan nuclear hormone receptors52,

128

. Members of this subgroup are

classified as early response genes, which are induced by a pleiotropy of stimuli, including
mitogens and inflammatory signals93, 129. In contrast to other members of the nuclear
receptor

superfamily,

NR4A

receptors

ligand-independent transcription factors45,

130

function

as

constitutively-active

and

. Therefore, the transcriptional activity of

NR4A receptors is determined by the expression level and by posttranslational
modifications of the receptor131. NR4A receptors positively regulate target gene expression
by binding as monomer or homodimer to different variations of the canonical
5’-A/TAAAGGTCA NGFI-B response element (NBRE)53. In addition, Nur77 (NR4A1)
and Nurr1 (NR4A2) exhibit transcriptionally distinct mechanisms, as both are able to
trans-activate target genes as a heterodimer with RXR132. Consistent with the pleiotropic
stimuli that induce the expression of NR4A receptors, these transcription factors have been
implicated in regulating key cellular functions, including inflammation, proliferation, and
cell survival52, 128.
NOR1 was first cloned from neuronal cells, and its deletion in mice results in
hippocampal dysgenesis and inner ear defects133, 134. In addition to neurons, NOR1 is
highly expressed in atherosclerotic lesions93, 94, 135, 136. NOR1 is induced by mitogens in
smooth muscle cells (SMC) and required for proliferative remodeling following vascular
injury93-95. In macrophages, NOR1 is induced during inflammation and represses cytokine
secretion129, 136. Finally, NOR1 expression is increased by vascular endothelial growth
factor (VEGF) in endothelial cells101. However, the functional role of NOR1 in endothelial
cells and its contribution to atherosclerosis remain to be investigated.
In the present study, we provide first evidence that NOR1 plays an essential role in the
regulation of monocyte adhesion to the endothelium by positively regulating VCAM-1 and
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ICAM-1 expression. In vivo, loss of NOR1 function in apoE-deficient mice reduces
atherosclerosis formation and macrophage recruitment to the arterial wall. These studies
identify NOR1 as a previously unrecognized key component of a transcriptional cascade
regulating monocyte adhesion during atherogenesis.
2.3. Material and Methods
Immunostaining
Immunostaining of human atherosclerotic lesions was performed as described
previously using primary antibodies against NOR1 (1:100 dilution; IMG-71915; Imgenex,
Inc.) or von Willebrand Factor (vWF) (1:100 dilution; 115-01, SIGNET)94,

95

. For

immunofluorescent co-localization studies, sections were incubated with primary
antibodies against NOR1 (1:50 dilution; ab56340; Abcam) and vWF (1:100 dilution;
115-01, SIGNET). Sections were subsequently incubated with Alexa 488-conjugated goat
anti-mouse antibody (1:1000 dilution, A11001, Invitrogen) and Alexa 594-conjugated goat
anti-rabbit antibody (1:1000, A11012, Invitrogen), respectively. All studies on human
tissues were performed with the approval of the University of Kentucky Institutional
Review Board.
For immunohistochemical analysis of mouse aortic atherosclerotic lesions, the
ascending aortae were embedded in OCT (Tissue-Tek; Miles Inc., Elkhart, Illinois, USA)
and snap-frozen. Transverse cryosections (10 µm) were collected from the aortic arch,
fixed in cold acetone, and immunostained using macrophage anti-sera (AI-AD 31240,
Accurate Chemicals) or a VCAM-1 antibody (BD 550547). All experiments on mice were
approved by the University of Kentucky Institutional Animal Care and Use Committee.
Cell culture
Human umbilical vein endothelial cells (HUVEC, Lonza) and human aortic
endothelial cells (HAEC, Cascade Biologics) were cultured as directed by the
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manufacturer. Human THP-1 monocytes (ATCC) were maintained in RPMI-1640 medium
supplemented with 10% FBS. Murine WEHI-274.1 premyelocytic cells (ATCC) were
cultured in DMEM supplemented with 10% FBS. Confluent endothelial cells were
stimulated with different cytokines or proinflammatory factors as indicated in the Figure
Legends. The reagents used in this study included human TNFα (R & D), human IL-1β (R
& D), human IL-6 (R & D), human IFNγ (R & D), human oxidized low-density-lipoprotein
(ox-LDL) (INTRACEL), mouse TNFα (R & D), mouse IL-1β (R & D) and LPS (Sigma).
All experiments were performed with cells between passages 2 to 8, and each experiment
was repeated at least three times with different preparations of cells.
Isolation of murine endothelial cells
Mouse aortic endothelial cells (MAEC) were isolated from aortae of littermate
NOR1+/+ and NOR-/- mice using an explant technique. Aortic segments were placed on
Cultrex Basement Membrane Extract gel (R & D Systems) and incubated in low-glucose
DMEM supplemented with 15 % FBS, 180 µg/ml heparin and 20 µg/ml endothelial cell
growth supplement. Migrated endothelial cells were passaged using dispase (BD Sciences)
and cultured for 2 days in media containing D-valine to limit fibroblast contamination.
Once confluent, MAEC were incubated with TNFα (R & D Systems) as indicated.
Western blotting
Western blotting was performed as described using antibodies against NOR1
(PP-H7833, R & D Systems), human VCAM-1 (BD Pharmingen), human ICAM-1
(Abcam), mouse VCAM-1 (R & D Systems), mouse ICAM-1 (Abcam), -actin (Sigma),
and GAPDH (FL 335) (Santa Cruz)94, 95.
Quantitative real-time RT-PCR
Total RNA was isolated using TRIzol® (Invitrogen) and reverse transcribed into
cDNA using SuperScript II (Invitrogen). RNA expression levels of target genes were
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quantified using an iQTM SYBR Green Supermix (BioRad) and 5 pmol of the indicated
primer pairs (Table 2.1). PCR reactions were performed on an iCycler (BioRad) using the
following PCR cycles: 1 cycle of 95 °C 10 min; 40 cycles of 95 °C 30 sec, 55 °C 30 sec,
72 °C 30 sec; 1 cycle of a final extension at 72°C for 10 min. Each sample was analyzed in
triplicate and normalized to expression values of the house-keeping gene TBP or TFIIB.
Data were calculated using the 2-∆∆CT method137.
Adenovirus-mediated over-expression in HUVEC
The

adenovirus

over-expressing

the

dominant-negative

IκBα

mutant

(IκBα-S32A/S36A) (Ad-CMV-IκB(DN)) was purchased from Vector Biolabs. The
adenovirus over-expressing human NOR1 (Ad-CMV-NOR1) was generously provided by
Dr. Peter Tontonoz (University of California, Los Angeles, CA). Sub-confluent HUVEC
were infected with 25 PFU Ad-CMV-IκB(DN) for 3 hours and 50 PFU Ad-CMV-NOR1
for 6 hours, respectively. Adenoviruses over-expressing GFP (Ad-CMV-GFP) or an empty
vector (Ad-CMV-null) were used as controls.
Plasmids, transient transfections and luciferase assay
The human NOR1 promoter constructs have previously been described94. The NF-κB
response elements located at -198bp to -190bp and -595bp to -496bp from the transcription
initiation site were mutated from GGAGTTTCC to AGAGTTTAA and from
GGGATTAGCC to ATGATTAGAA using the QuickChange II XL site–directed
mutagenesis kit (Stratagene). HAEC were transiently transfected with NOR1 promoter
constructs using promofectin (PromoKine). Following transfection, cells were recovered
overnight and stimulated with TNFα. The human VCAM-1 promoter construct was
commercially obtained from Epoch Biolabs Company. The NBRE site located at -2618 bp
to -2611 bp from the transcription initiation site was mutated from TGACCTTT to
TCGGAGTT. For overexpression of NOR1, HUVEC were infected with 50 PFU
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Ad-CMV-Null or Ad-CMV-NOR1 for 6 hours and recovered for 24 hours. Infected cells
were subsequently transfected with luciferase reporter constructs driven by the VCAM-1
promoter. Following transfection, cells were recovered in growth media for 2 days.
Luciferase activities were analyzed using a Dual Luciferase Reporter Assay (Promega).
Transfection efficiency was normalized to renilla luciferase activities generated by
cotransfection of 5 ng pRLCMV.
siRNA experiments
siRNA experiments were performed using the SMARTpool technology (L003428,
Dharmacon RNA Technologies), which provides a mix of four different proprietary
siRNAs specific against human NOR1. HUVEC were seeded at a density of 1.2 × 105
cells/well in 6-well plates and transiently transfected for 3 h with 30 nM NOR1 siRNA or
scrambled siRNA using promofectin (PromoKine). Following transfection, cells were
recovered in complete growth media overnight and subsequently stimulated with TNFα for
6 h. Fluorescently labeled THP-1 monocytes were added onto the HUVEC monolayers and
adhesion was quantified after 30 min as indicated in the section "Adhesion assay".
Chromatin immunoprecipitation (ChIP) assays
ChIP assays were performed using the EZ-ChIP kit (Millipore) as described94, 95.
Briefly,

HUVEC

were

stimulated

with TNFα

and

sheared

chromatin

was

immunoprecipitated using 5 µg antibodies directed against NF-κB p65 (sc-372x, Santa
Cruz) or NOR1 (PP-H7833, R & D Systems). Target DNA product was amplified by PCR
using primer pairs covering the NF-κB binding sites in the NOR1 promoter or the NBRE
site in the VCAM-1 promoter (Table 2.1).
Adhesion assay
HUVEC were infected with 50 PFU Ad-CMV-Null or Ad-CMV-NOR1 for 6 hours
and recovered for 48 hours. HUVEC treated with TNFα were employed as a positive
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control. THP-1 monocytes were pre-stained with 5 µM calcein-AM (Sigma-Aldrich) at
37 °C for 30 minutes. After washing in PBS, fluorescently labeled THP-1 monocytes were
added onto the HUVEC monolayers at the density of 106 cells/ml. To block VCAM-1 and
ICAM-1 function, HUVEC monolayers were incubated with blocking antibodies against
VCAM-1 (25 µg/ml, BBA5, R & D Systems) and ICAM-1 (10 µg/ml, BBA3, R & D
Systems) for 1 hour prior to the addition of THP-1 monocytes. Non-adherent monocytes
were washed off after 30 minutes. For mouse monocyte adhesion assays the thoracic aortae
of littermate NOR1+/+ or NOR1-/- mice were cut into segments, pinned on dental wax,
and maintained in MAEC growth media supplemented with TNFα (1 ng/ml) or vehicle
(PBS). After 6 hours, aortae were washed with PBS, and 700 µl of fluorescently labeled
WEHI-274.1 cells were added at the density of 106 cells/ml. Non-adherent monocytes were
removed after 30 minutes by washing with PBS. For both experiments, six pictures were
taken for each condition, and adhesion was quantified by counting fluorescent monocytes
attached to the endothelium.
Mice
Littermate NOR1-/- and NOR1+/+ mice on a mixed C57BL/6J/129Sv background
were used as previously described94, 95. ApoE-/- mice on a C57BL/6J background (N10)
were obtained from The Jackson Laboratory (stock #002052) and interbred with NOR1-/mice to obtain NOR1-/-apoE-/- mice. At 8 to 10 weeks of age, littermate female
NOR1+/+apoE-/-, NOR1+/-apoE-/- and NOR1-/-apoE-/- mice were fed a saturated fat
enriched diet (TD88137; Harlan Teklad) for 12 weeks for atherosclerosis analysis or for 2
weeks to analyze NR4A gene expression.
Atherosclerosis quantification
Atherosclerosis was quantified as described and reviewed recently in detail138, 139.
Briefly, after exsanguination aortic tissue was removed from the ascending aorta to the
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ileal bifurcation and fixed by perfusion with freshly prepared 4 % paraformaldehyde in
PBS overnight at room temperature. After tissue fixation, the aorta was dissected from the
adventitia. The intimal surface was exposed by a longitudinal cut through the inner
curvature of the aortic arch that extended down the whole length of the aortic tree. To
permit the arch region to be laid out flat, the greater curvature was cut down to the level of
the subclavian artery. The tissue was laid out, and an image of the aorta was recorded. To
quantify the extent of intimal surface covered by grossly discernible lesions, image
analysis was performed with Image-Pro (Media Cybernetics). The extent of atherosclerotic
lesions was quantified in the arch as defined from the ascending arch to 4 mm distal to the
left subclavian artery. The data were presented as the percentage of lesion area on the aortic
arch.
Quantification of macrophage accumulation
Macrophage content was quantified in a 2-mm segment as defined from the beginning
of the ascending aortic arch using a modified technique described by Mach et al140. From
this segment 180 serial transverse cryosections (10 μm) were collected and placed onto
twenty slides per mouse. Slides were immunostained for macrophages as described above,
and the macrophage content was quantified in nine sections 200 µm apart. Macrophage
accumulation was determined by quantifying the total area positive for macrophage
staining using computer-assisted image analysis (Image-Pro, Media Cybernetics). Each
section was quantified by two observers blinded to the experimental design. The data were
presented as mean area ± SEM positive for macrophage staining for each of the nine
measurements and their cumulative sum.
Lipoprotein resolution and quantification
Lipoproteins were resolved using size exclusions chromatography as described138,
139

. Briefly, serum samples were centrifuged and placed onto a single Sepharose 6 HR

10/30 column (300 x 10 mm, Pharmacia) with a mobile phase of saline/EDTA run at 0.5
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ml/min. Fractions (0.5 ml) were collected and cholesterol concentrations were determined
by placing 100 µl of each fraction into an equivalent volume of cholesterol reagent (Wako
Chemical Company) that was diluted to half the manufacturer’s instructions. Assays were
performed in a 96 well format and absorbance was determined at 600 nm.
Statistical analysis
Results were represented as means or medians depending on the distribution of data.
Unpaired Student’s t-test was utilized to compare the means between two independent
groups on a single variable. One-way or Two-way ANOVA was used to compare groups.
The effect of NOR1 on atherosclerosis was compared using the Kruskal-Wallis test
followed by Dunn Test post-hoc analysis. P values < 0.05 were considered to be
statistically significant.
2.4. Results
NOR1 is expressed in endothelial cells of human coronary atherosclerotic lesions
To characterize the distribution of NOR1 expression in atherosclerosis, human
coronary arteries were immunostained for NOR1. NOR1 protein was readily detectable in
atherosclerotic lesions (Figure 2.1A) but negligible in normal arteries (data not shown). In
these atherosclerotic sections, high levels of NOR1 immunostaining were observed in the
endothelial cell layer and in sub-endothelial cells of advanced atherosclerotic lesions.
Colocalization experiments using confocal microscopy confirmed a typical nuclear
expression pattern of NOR1 in endothelial cells staining positive for the endothelial cell
marker vWF (Figure 2.1B).
NOR1 is induced by inflammatory stimuli in endothelial cells
In vitro, stimulation of HUVEC with the inflammatory mediators IL-1β, oxidized
LDL, LPS, or TNFα highly induced NOR1 mRNA expression (Figure 2.2A). In contrast,
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IL-6 or IFN-γ did not significantly induce NOR1 transcript levels in HUVEC. Considering
that TNFα elicited a maximal increase in NOR1 expression, subsequent experiments
focused on the regulation of NOR1 by TNFα. Consistent with previous reports
characterizing NOR1 as an early response gene93, 129, time-course experiments confirmed a
maximal induction of NOR1 mRNA after 3 h of TNFα stimulation (Figure 2.2B). This
increase in NOR1 transcript levels was followed by a maximal induction of NOR1 protein
expression after 6 h (Figure 2.2C-D). The observed regulation of NOR1 mRNA and protein
expression by TNFα was dose-dependent revealing a maximal increase of NOR1
expression with 1 ng/ml TNFα (Figure 2.2E-G, respectively). Finally, TNFα induced a
similar induction of NOR1 mRNA expression in primary MAEC isolated from NOR1
wildtype mice (Figure 2.2H). In contrast, the other two members of the NR4A subfamily
Nur77 and Nurr1 were only modestly induced in NOR1 wildtype cells, and this induction
was lost in NOR1-/- MAEC.
NOR1 expression in endothelial cells is mediated through an NF-κB-dependent
trans-activation of the NOR1 promoter
NOR1 is primarily regulated through transcriptional mechanisms, and sequence
analysis of the NOR1 promoter identified several putative NF-κB binding sites. To address
the functional relevance of these NF-κB sites, endothelial cells were infected with an
adenoviral construct over-expressing a dominant-negative IκBα mutant. In cells
over-expressing GFP as control, TNFα treatment resulted in a significant increase of
NOR1 mRNA expression (Figure 2.3A). In contrast, over-expression of the
dominant-negative IκBα mutant resulted in an almost complete inhibition of
TNFα-induced NOR1 mRNA expression. These experiments indicate that TNFα-induced
NOR1 expression is primarily mediated via NF-κB signaling in endothelial cells.
To further confirm an NF-κB-dependent transcriptional regulation of NOR1
expression in endothelial cells, we performed transient transfection assays using a NOR1
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promoter construct. This 4.0 kb full-length human NOR1 promoter construct includes two
putative NF-κB binding sites at -595 to -586 and -198 to -190 from the transcription
initiation site (Figure 2.3B). Stimulation of endothelial cells with TNFα resulted in a
significant activation of the full-length NOR1 promoter (Figure 2.3C). This induction of
the NOR1 promoter was maintained upon 5’-deletion to 1.7 kb but completely abolished
following mutation of the two NF-κB binding sites, confirming that TNFα induces NOR1
promoter activity via an NF-κB-dependent trans-activation of the promoter. As depicted in
Figure 2.3D and E, ChIP assays revealed the recruitment of p65 to the NF-κB site in the
endogenous NOR1 promoter in response to TNFα. Maximal promoter occupancy was
observed after 3 h, which is consistent with the kinetics of NOR1 mRNA expression in
response to inflammatory stimuli. In concert, these data demonstrate that TNFα induces
NOR1 expression through a NF-κB-dependent signaling pathway resulting in the
subsequent trans-activation of the proximal NOR1 promoter.
NOR1 positively regulates VCAM-1 and ICAM-1 in endothelial cells
To explore whether NOR1 is involved in the transcriptional control of endothelial cell
responses, we next infected HUVEC with an adenovirus overe-xpressing human NOR1
(Figure 2.4A). As depicted in Figure 2.4B-E, NOR1 over-expression resulted in a
prominent induction of VCAM-1 and ICAM-1 mRNA and protein expression levels,
respectively.
We next employed a murine model to address whether NOR1 is also required for
VCAM-1 and ICAM-1 expression in endothelial cells. In these experiments, MAEC were
isolated from littermate NOR1 wildtype and NOR1-deficient mice94, 95. As depicted in
Figure 2.5A-E, TNFα stimulation profoundly increased VCAM-1 and ICAM-1 mRNA
and protein expression in NOR1 wildtype MAEC. In contrast, the induction of both
adhesion molecules was markedly reduced in MAEC isolated from NOR1-deficient mice.
Similar data were obtained when cells were stimulated with IL-1β or LPS (Figure 2.5F-H).
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NOR1 trans-activates the VCAM-1 promoter by binding to a canonical NBRE
consensus site
We next performed transient transfection assays to investigate the underlying
mechanism by which NOR1 regulates VCAM-1 expression in endothelial cells. NOR1
induces transcription by binding to NBRE consensus sites in target gene promoters53.
Interestingly, sequence analysis of the human VCAM-1 promoter identified a canonical
NBRE site at -2618 bp from the transcription initiation site (Figure 2.6A). Transient
transfection of HUVEC with a luciferase reporter construct driven by the human 3.0 kb
VCAM-1 promoter revealed that over-expression of NOR1 increases VCAM-1 promoter
activity (Figure 2.6B). However, this transcriptional induction was significantly altered
upon site-directed mutagenesis of the canonical NBRE motif. ChIP assays subsequently
confirmed that TNFα induced the recruitment of NOR1 to this NBRE site in the VCAM-1
promoter (Figure 2.6C). These experiments demonstrate that NOR1 trans-activates the
VCAM-1 promoter by binding to a NBRE consensus site in the promoter and characterize
VCAM-1 as NOR1-regulated target gene.
NOR1 mediates monocyte adhesion by regulating VCAM-1 and ICAM-1 expression
VCAM-1 and ICAM-1 have both been well characterized to mediate monocyte
adhesion to the endothelium leading to the infiltration of monocytes into the
sub-endothelial area and atherosclerosis development141. To investigate whether the
transcriptional induction of VCAM-1 and ICAM-1 by NOR1 is sufficient to promote
monocyte adhesion, we analyzed THP-1 monocyte adhesion to HUVEC over-expressing
NOR1. Stimulation of a HUVEC monolayer with TNFα profoundly increased monocyte
adhesion, confirming the validity of the assay (Figure 2.7A, upper panel). Compared to
HUVEC infected with an adenovirus over-expressing an empty vector as control,
overexpression of NOR1 significantly increased monocyte adhesion in the absence of
TNFα stimulation (Figure 2.7A and B). Furthermore, monocyte adhesion induced by
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NOR1 over-expression was almost completely abolished by pre-incubation of HUVEC
with VCAM-1 and ICAM-1 blocking antibodies (Figure 2.7A and 2.7B). Conversely, acute
knock-down of NOR1 in HUVEC using siRNA significantly decreased monocyte adhesion
(Figure 2.7C-D). Collectively, these studies indicate that NOR1 is necessary and sufficient
for monocyte adhesion and that this activity is mediated primarily by inducing the
expression of VCAM-1 and ICAM-1.
To further confirm a causal contribution of NOR1-dependent VCAM-1 and ICAM-1
expression for monocyte adhesion ex vivo, we performed adhesion assays with aortae
isolated from NOR1+/+ and NOR1-/- mice. Incubation with TNFα significantly increased
the adhesion of monocytes to the aortic endothelial cell layer of NOR1 wildtype mice
(Figures 2.7E-F). However, this inducible adhesion was completely abolished on aortae of
NOR1-deficient mice. From these findings we infer that NOR1 expression in resident
endothelial cells is necessary for mediating monocyte adhesion.
NOR1 deficiency decreases atherosclerosis formation and reduces macrophage
recruitment in apoE-/- mice
Considering that monocyte adhesion constitutes a critical initial step for
atherogenesis141.

We

next

investigated

whether

NOR1-deficiency

decreases

atherosclerotic lesion development. Consistent with the important function of NOR1 to
regulate monocyte adhesion ex vivo, homozygous deletion of NOR1 in apoE-/- mice
resulted in a 52 % reduction of atherosclerosis compared to their wildtype littermates
(NOR1+/+apoE-/- 14.3 % (n=14), NOR1+/-apoE-/- 14.0 % (n=15), and NOR1-/-apoE-/6.8 % (n=15) median atherosclerotic lesion area of aortic arches; P < 0.05; Figure 2.8A-B).
NOR1-deficiency revealed no overt effect on cholesterol distribution confirming a direct
effect of NOR1 on lesion formation (Figure 2.8C). Immunostaining of atherosclerotic
tissues and quantification of the macrophage content confirmed macrophage-enriched
lesions in NOR1+/+apoE-/- mice that were considerably less with decreased macrophage
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content in NOR1-/-apoE-/- mice (Figure 2.8D-F). Finally, while VCAM-1 was readily
detectable in atherosclerotic lesions from NOR1+/+apoE-/- mice, there was a paucity of
immunoreactivity for this adhesion molecule noted in the vascular wall of NOR1-/-apoE-/mice (Fig. 2.8G).
2.5. Discussion
Monocyte adhesion constitutes a critical event for the initiation of atherosclerosis141;
however, the molecular mechanisms that orchestrate monocyte-endothelial cell
interactions are incompletely understood. In the present study, we report a previously
unrecognized role for the nuclear receptor NOR1 to serve as a transcriptional regulator of
adhesion molecule expression and monocyte recruitment during atherosclerosis. In
endothelial cells, NOR1 is rapidly induced by inflammatory stimuli via an
NF-κB-dependent trans-activation of the NOR1 promoter. Loss and gain-of-function
studies establish that NOR1 positively regulates VCAM-1 and ICAM-1 expression in
endothelial cells leading to increased monocyte adhesion. Consistent with the key role of
NOR1 to promote monocyte adhesion to the endothelium, our studies further demonstrate
that NOR1 deficiency results in decreased atherosclerosis development and macrophage
recruitment in apoE-deficient mice.
Consistent with recent studies, we identified abundant NOR1 expression in
endothelial cells135 as well as in cells of the sub-endothelial space likely representing
macrophages and SMC91, 94, 96, 97, 135. However, the transcriptional mechanisms governing
inducible NOR1 expression in endothelial cells remain elusive. Our data provides evidence
for an NF-κB-dependent induction of NOR1 transcription during endothelial cell
inflammation. Inhibition of NF-κB signaling in endothelial cells repressed inducible
NOR1 expression in response to inflammatory stimulation. Using site-directed
mutagenesis and ChIP assays, we identified two functional NF-κB sites in the NOR1
promoter, to which p65 is recruited during inflammatory activation of endothelial cells.
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Earlier studies have demonstrated that NOR1 expression in endothelial cells is highly
induced

by

mitogens

through

a

cAMP

response

element

binding

protein

(CREB)-dependent activation of the proximal region of NOR1 promoter101. Furthermore,
hypoxia has recently been reported to induce NOR1 in endothelial cells through a
mechanism involving the hypoxia-inducible factor (HIF) family of transcription factors142.
These studies, in concert with our data characterizing NOR1 as an NF-κB target gene in
endothelial cells, point to distinct transcriptional mechanisms regulating the rapid NOR1
induction in response to various environmental cues.
Compared with the well-studied early-response genes encoding proteins of the AP-1
complex, little is known about the physiological function of NOR1 and its regulated target
genes, yet the high degree of conservation points to an important role in the control of gene
expression. A previous study has provided initial evidence to support a functional role of
NOR1 in endothelial cells by demonstrating that NOR1 regulates growth of this cell type101.
The data presented here extends these findings and points to an unsuspected function of
NOR1 to serve as a positive regulator of monocyte adhesion. In experiments using
adenoviral-mediated over-expression, NOR1 induced VCAM-1 and ICAM-1 expression
resulting in increased monocyte adhesion. The observation that this inducible adhesion
was abolished when VCAM-1 and ICAM-1 function were blocked, suggests that the
induction of both adhesion molecules by NOR1 constitutes a primary mechanism by which
NOR1 induces monocyte adhesion. Conversely, the inducible expression of both adhesion
molecules in response to inflammatory activation was attenuated in NOR1-deficient
endothelial cells. Furthermore, consistent with these findings, TNFα-induced monocyte
adhesion to HUVEC transfected with NOR1 siRNA or to the endothelium of
NOR-deficient mice was altered ex vivo, suggesting that vascular NOR1 expression is not
only sufficient but also required for monocyte adhesion.
An intriguing question that arises from the observation that NOR1 induces the
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expression of VCAM-1 and ICAM-1 relates to the mechanisms by which NOR1 positively
regulates these genes. Initial sequence analysis identified putative NBRE consensus sites
in both the VCAM-1 and ICAM-1 promoters. Exemplified by the VCAM-1 promoter, our
studies demonstrate that the molecular mechanisms underlying this novel function of
NOR1 involve at least in part a direct trans-activation of the VCAM-1 promoter by NOR1.
In response to inflammatory activation NOR1 is recruited to a canonical NBRE site in the
VCAM-1 promoter. Moreover, the observation that NOR1-dependent VCAM-1 promoter
trans-activation was attenuated upon mutation of this NBRE site confirms the functionality
of this NBRE motif. However, the residual induction of the VCAM-1 promoter bearing a
mutation of this NBRE site suggests that additional transcriptional mechanisms may
regulate NOR1 expression. NOR1 has recently been shown to trans-activate the inducible
IκB kinase (IKKi/IKKepsilon) promoter, which phosphorylates IκBα and induces NF-κB
activation143. Therefore, in addition to a direct trans-activation, NOR1 may function as a
positive upstream regulator of NF-κB signaling and indirectly activate the VCAM-1 and
ICAM-1 promoters. Alternatively, NOR1 deficiency may affect other transcriptional
networks acting on these promoters, including for example the AP-1 complex. We have
recently demonstrated that the combined deficiency of NOR1 and its sibling Nur77
decreases the expression of AP-1 transcription factors121, which may regulate adhesion
molecule expression144. Clearly, the findings presented here provide justification for
further investigating the transcriptional mechanisms by which NOR1 regulates endothelial
cell gene expression and promotes monocyte adhesion.
The protein products of the VCAM-1 and ICAM-1 genes are well established to
participate in atherogenesis by promoting macrophage accumulation in the arterial
intima141. Consistent with this evidence and with the observed regulation of endothelial
cell adhesion molecule expression by NOR1, we provide the first evidence that NOR1
deficiency decreases atherosclerosis in apoE-deficient mice. Considering that all three

36

members of the NR4A receptor subfamily bind to an NBRE site, functional redundancy in
certain cell types between Nur77 and NOR1 has been suggested114. However,
NOR1-deficiency did not result in a compensatory upregulation of the siblings Nur77 and
Nurr1 in endothelial cells (Figure 2.2H) or in the aortae of NOR1-/-apoE-/- mice (Figure
2.9). Therefore, the previously reported phenotypes in NOR1-deficient mice95, 133, 134. In
concert with the decreased atherosclerosis in NOR1-/-apoE-/- mice presented in this study,
point to a function of NOR1 that is distinct and not compensated by Nur77 or Nurr1. As
evidenced by the decreased accumulation of macrophages in the vascular wall of
NOR1-/-apoE-/- mice, monocyte recruitment represents at least one plausible mechanism
by which NOR1 acts atherogenic. However, it is possible if not likely that there are
additional mechanisms by which NOR1 promotes atherosclerosis development. NOR1
induces neointimal proliferation of SMC

95

and inflammatory gene expression in

macrophages143, which both could affect lesion development. Therefore, characterization
of the cell-specific role of NOR1 in atherosclerosis will be necessary and will have to rely
on tissue-specific gene targeting strategies. In conclusion, data presented here characterize
the orphan nuclear receptor NOR1 as a novel positive regulator of monocyte adhesion by
inducing VCAM-1 and ICAM-1 transcription. Continued investigation of the
transcriptional networks regulated by NOR1 will provide new insights into how this
orphan nuclear receptor participates in the development of vascular diseases.
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Table 2.1. Oligonucleotides used in this study

Name

Use

Sequence

human NOR1

Real-time
RT-PCR

F : 5’-GGGCTTTTTCAAGAGAACAGTG-3’
R: 5’-ATCTCTGGGTGTTGAGTCTGTT-3’

human VCAM-1

Real-time
RT-PCR

F: 5’-TGAGGGGACCAATTCCAC-3’
R: 5’-ATTCACGAGGCCACCACT-3’

human ICAM-1

Real-time
RT-PCR

F: 5’-ACCGTGAATGTGCTCTCC-3’
R: 5’-GGCTTGTGTGTTCGGTTT-3’

murine VCAM-1

Real-time
RT-PCR

F: 5’-TCAAAGAAAGGGAGACTG-3’
R: 5’-GCTGGAGAACTTCATTATC-3’

murine ICAM-1

Real-time
RT-PCR

F: 5’-AGATCACATTCACGGTGCTG-3’
R: 5’-CTTCAGAGGCAGGAAACAGG-3’

human TBP

Real-time
RT-PCR

F: 5’-GGAGAGTTCTGGGATTGTACCGC-3’
R: 5’-ATATTCGGCGTTTCGGGCAC-3’

murine TFIIB

Real-time
RT-PCR

F: 5’-CTCTCCCAAGAGTCACATGTCC-3’
R: 5’-CAATAACTCGGTCCCCTACAAC -3’

murine NOR1

Real-time
RT-PCR

F: 5’-GGCCGCAGCTGCACTCAGTC -3’
R: 5’-GCGGAGGGAAGGTCAGCGTG -3’

murine Nur77

Real-time
RT-PCR

F: 5’-TTGATGTTCCCGCCTTTG-3’
R: 5’-GGTAGCCATGTGCTCCTTC-3’

murine Nurr1

Real-time
RT-PCR

F: 5’-TCACCTCCGGTGAGTCTGATC-3’
R: 5’-TGCTGGATATGTTGGGTATCATCT-3’

hNOR1-NFKB

ChIP PCR

F: 5’-CCATCTGCATCCCTGTGT-3’
R: 5’-GCTGCACTTTCCTCTTGC-3’

hVCAM-1-NOR1

ChIP PCR

F: 5’-CTGTACTCAAACATTGGAAACATT -3’
R: 5’-CCTTAGAGATGAGAGAAGCAAGA-3’
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Figure 2.1. NOR1 is present in endothelial cells of human coronary atherosclerotic
lesions
Sections of atherosclerotic human coronary arteries were immunostained for NOR1 and
von Willebrand Factor (vWF) to identify endothelial cells. Species-matched normal IgG
served as negative control. Images were acquired using (A) light microscopy and (B)
confocal microscopy. In (B) stainings for NOR1, vWF and DAPI were merged into one
image as indicated. Objective magnifications are indicated.
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Figure 2.2. NOR1 is induced by inflammatory stimuli in endothelial cells
(A) HUVEC were stimulated as indicated for 2 hours and NOR1 mRNA expression was
analyzed. (B-D) HUVEC were stimulated with TNFα (1 ng/ml) and NOR1 mRNA (B) and
protein expression (C) were analyzed at the indicated time points. (D) Densitometric
analysis of NOR1 protein expression in (C). (E-G) HUVEC were stimulated with vehicle
(PBS) or the indicated doses of TNFα. NOR1 mRNA (E) and protein (F) expression were
analyzed after 2 hours or 6 hours, respectively. (G) Densitometric analysis of NOR1
protein expression in (F). NOR1 mRNA expression levels were normalized to hTBP and
presented as mean ± SEM fold increase over vehicle-treated cells (*P < 0.05 vs. vehicle).
Densitometric analysis was performed on three independent experiments. Cohybridization
for GAPDH was performed to assess equal loading. (H) NOR1+/+ and NOR1-/- MAEC
were incubated with TNFα (5 ng/ml) and mRNA expression of NOR1, Nur77 and Nurr1
was analyzed by real-time RT-PCR. Experiments were repeated at least three times in
duplicate with different cell preparations. Results are presented as mean ± SEM fold
increase over vehicle-treated wildtype cells (*P < 0.05 vs. vehicle).
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Figure

2.3.

NOR1

expression in

endothelial

cells

is

mediated

through

NF-κB-dependent signaling pathways
(A) HUVEC were infected with 25 PFU Ad-CMV-IκB(DN) or Ad-CMV-GFP and
stimulated with vehicle (PBS) or TNFα (1 ng/ml) for 2 hours. NOR1 mRNA expression
was analyzed and normalized to hTBP. Data are presented as mean ± SEM fold increase
over Ad-CMV-GFP-infected cells treated with vehicle (*p < 0.05 vs. vehicle; #p < 0.05 vs.
Ad-CMV-GFP). (B) Schematic structure of the human 4.0 kb and 1.7 kb NOR1 promoter
constructs. (C) HAEC were transfected with a luciferase reporter construct driven by the
indicated NOR1 promoter, stimulated with vehicle (PBS) or TNFα (10 ng/ml), and
analyzed for luciferase activities. Data are presented as mean ± SEM from three
independently performed experiments (*p < 0.05 vs. vehicle; #p < 0.05 vs.
pNOR1-1.7kb-WT). (D-E) HUVEC were stimulated with TNFα (1 ng/ml) and harvested
at

the

indicated

time

point

for

ChIP assays.

Chromatin

complexes

were

immunoprecipitated with an antibody against NF-κB p65 or species-matched IgG. PCR
products were amplified using primers covering the -595 bp to -586 bp NF-κB binding site.
(D) The autoradiograms are representative of three independently performed experiments.
(E) Densitometric analysis of NF-κB p65 binding normalized to input from three
independently performed experiments.
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Figure 2.4. NOR1 induces VCAM-1 and ICAM-1 expression in endothelial cells
(A-E) HUVEC were infected with 50 PFU Ad-CMV- NOR1 or Ad-CMV-GFP. (A)
Western Blotting confirmed NOR1 over-expression after transduction. (B) VCAM-1 and
ICAM-1 mRNA expression was determined by real-time RT-PCR. Experiments were
performed at least three times in triplicate. Data were calculated by normalizing NOR1
values to hTBP values and presented as mean ± SEM fold induction over Ad-CMV-GFP
infected cells (*p < 0.05 vs. Ad-CMV-GFP). (C-E) VCAM-1 and ICAM-1 protein
expression was analyzed by Western blotting. Cohybridization for actin was performed to
assess equal loading. (C) Representative autoradiograms and densitometric analysis (D
and E) of three independently performed experiments.
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Figure 2.5. NOR1 is required for VCAM-1 and ICAM-1 expression in endothelial
cells
(A-E) NOR1+/+ and NOR1-/- MAEC were stimulated with vehicle or TNFα (1 ng/ml) for
6 hours. VCAM-1 and ICAM-1 mRNA (A and B) and protein (C-E) expression were
analyzed by real-time RT-PCR and Western blotting, respectively. (C) The autoradiograms
are representative of three independent experiments. (D and E) Densitometric analysis of
VCAM-1 and ICAM-1 protein expression after Western blotting. All experiments were
repeated at least three times in duplicate with different cell preparations. Results are
presented as mean ± SEM fold increase over vehicle-treated wildtype cells (*P < 0.05 vs.
vehicle, # P < 0.05 vs. NOR1+/+ cells). (F-H) NOR1+/+ and NOR1-/- MAEC were
stimulated with vehicle, IL-1β (1 ng/ml), or LPS (50 ng/ml) for 6 hours. VCAM-1 and
ICAM-1 protein expression were analyzed by Western blotting. Cohybridization for actin
was performed to assess equal loading. (F) Autoradiograms are representative of three
different experiments. (G and H) Densitometric quantification of VCAM-1 and ICAM-1
protein expression from three experiments with different cell preparations. Results are
presented as mean ± SEM fold increase over vehicle-treated wildtype cells (*P < 0.05 vs.
vehicle, # P < 0.05 vs. NOR1+/+ cells).
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Figure 2.6. NOR1 trans-activates the VCAM-1 promoter by binding to an NBRE
consensus site
(A) Schematic structure of the human 3.0 kb VCAM-1 promoter and the NBRE consensus
site at -2618 bp. (B) HUVEC were infected with 50 PFU Ad-CMV-Null or
Ad-CMV-NOR1 for 6 hours and recovered for 24 hours. Infected cells were transiently
transfected with luciferase reporter constructs driven by the VCAM-1 wildtype promoter
or the similar promoter bearing a mutation in the NBRE site. Luciferase activities were
analyzed after 48 hours. Data are presented as mean ± SEM fold induction from three
independently performed experiments (*p < 0.05 vs. empty vector; #p < 0.05 vs.
pVCAM-1-WT). (C) HUVEC were stimulated with vehicle (PBS) or TNFα (1 ng/ml) for
ChIP assays. PCR for an unrelated promoter fragment in the β-actin promoter served as
control for specificity. The autoradiograms are representative of three independently
performed experiments.
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Figure 2.7. NOR1 mediates monocyte adhesion by regulating VCAM-1 and ICAM-1
expression
(A) Upper panel: HUVEC were infected with 50 PFU Ad-CMV-NOR1 or Ad-CMV-Null,
and fluorescently labeled THP-1 monocytes were added onto HUVEC monolayers.
TNFα-treated (1 ng/ml) HUVEC were employed as a positive control. Lower panel:
Ad-CMV-NOR1-infected cells were pre-incubated with VCAM-1 and ICAM-1 blocking
antibodies (B/N) or control IgG. After 1 hour, fluorescently labeled THP-1 monocytes were
added onto HUVEC monolayers. (B) Quantification is presented as mean ± SEM from
three independently performed experiments in duplicate (*p < 0.05 vs. vehicle or
Ad-CMV-Null, # p < 0.05 vs. TNFα, § p < 0.05 vs. IgG). (C and D) siRNA-mediated
knock-down of NOR1 expression decreased monocyte adhesion. (C) HUVEC were
transfected with scrambled or NOR1 siRNA, stimulated with TNFα (1 ng/ml), and
analyzed for THP-1 monocyte adhesion. Representative images showing monocyte
adhesion. (D) Quantification is presented as mean ± SEM from three independently
performed experiments in duplicates (*P < 0.05 vs. vehicle, # P < 0.05 vs. scrambled
siRNA). (E and F) Aortae were isolated from NOR1+/+ and NOR1-/- mice and
TNFα-induced monocyte adhesion was analyzed. (E) Representative sections
demonstrating adhesion of monocytes. (F) Quantification of adhesion from three
independent experiments performed in duplicate using different aortic preparations. Data
are expressed as mean ± SEM (*P < 0.05 vs. vehicle, # P < 0.05 vs. NOR1+/+ cells).
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Figure 2.8. NOR1 deficiency decreases atherosclerosis in apoE-/- mice
(A) Atherosclerotic lesion size was measured on aortic arches from female
NOR1+/+apoE-/- (n=14), NOR1+/-apoE-/- (n=15) and NOR1-/-apoE-/- (n=15) mice.
Circles and triangles represent individual mice; diamonds represent medians (P < 0.05
between group, *P < 0.05 vs. NOR1+/+apoE-/-). (B) Representative aortic arches from
each genotype. (C) Lipoprotein cholesterol distributions. Values represent the mean
cholesterol content of each fraction (± SEM). (D-G) Serial sections from a 2-mm segment
beginning at the lesser curvature of the aortic arch were collected from NOR1+/+apoE-/and NOR1-/-apoE-/- mice. Sections of atherosclerotic lesions were immunostained using
antisera against macrophages or VCAM-1. (D) Representative sections for macrophage
staining (top) or IgG (bottom) (objective magnification ×20). (E) Macrophage content was
quantified in nine sections 200 µm apart using computer-assisted image analysis. Data are
presented as mean area in mm2 ± SEM. Statistical analysis was performed using factorial
ANOVA test. No significant difference between single segments of the arch in
NOR1+/+apoE-/- and NOR1-/-apoE-/- mice was detected. (F) Macrophage accumulation
was quantified in the entire aortic arch from NOR1+/+apoE-/- and NOR1-/-apoE-/- mice
(*P < 0.05 vs. NOR1+/+apoE-/-). (G) Representative sections for VCAM-1 staining
(objective magnification ×20 and x100).
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Figure 2.9. The expression of NR4A nuclear receptors in mouse aortic arteries in
response to high-fat diet feeding
NOR1+/+apoE-/- (n=5) and NOR1-/-apoE-/- (n=5) mice were fed a diet enriched in
saturated fat for 2 weeks. Aortae were collected and mRNA expression of NOR1, Nur77
and Nurr1 was analyzed by real-time RT-PCR. Results are presented as mean ± SEM fold
increase over NOR1+/+apoE-/- mice. Note, no NOR1 transcript was detected in
NOR1-/-apoE-/- mice (N.D., not detectable).
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Chapter three: Epigenetic regulation of the NR4A orphan nuclear receptor NOR1 by
histone deacetylase inhibition
This part is in manuscript preparation for submission.
3.1. Synopsis
Many nuclear receptors function as key transcriptional regulators of gene expression
in cardiovascular diseases. While most nuclear receptors are ligand-dependent
transcription factors, members of the NR4A subfamily function as immediate/early
response genes whose transcriptional activity is dependent on their expression level or
their posttranslational modification. In our previous studies, we established that the
neuron-derived orphan receptor 1 (NOR1) of the NR4A subfamily serves a mitogenic role
and promotes neointima formation. In smooth muscle cells, NOR1 is induced through
phosphorylation of the cAMP response element binding protein (CREB) and subsequent
binding of phosphorylated CREB to the NOR1 promoter. In the current study, we extend
these observations and demonstrate that NOR1 expression is enhanced by inhibition of
histone deacetylation. Pre-treatment of smooth muscle cells with the histone deacetylase
(HDAC) inhibitor scriptaid potentiated and sustained PDGF-induced NOR1 mRNA and
protein expression. Conversely, specific small interfering RNA-mediated knockdown of
HDAC3 augmented PDGF-induced NOR1 mRNA expression. Scriptaid increased NOR1
promoter activity in reporter assays without affecting NOR1 transcript stability. This
increased NOR1 transcription was associated with enhanced CREB phosphorylation by
HDAC inhibition. Chromatin immunoprecipitation assays further confirmed that HDAC
inhibition increased histone acetylation at CREB binding sites in the NOR1 promoter
region and results in increased binding of phosphorylated CREB to its consensus sites.
Finally, we demonstrate that HDAC inhibition also increases NOR1 protein half-life.
Collectively, these data suggest that HDAC inhibition increases NOR1 expression at
multiple levels, including gene transcription and protein stability. These findings may have
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important implications for understanding the epigenetic mechanisms orchestrating the
expression of this mitogenic transcription factor.
3.2. Introduction
Epigenetic traits are considered as chromosome modifications that regulate gene
transcription without altering DNA sequences30, 42. These modifications can be translated
into signals dictating gene activation/repression30, 42. One factor involved in epigenetic
regulation is the chemical modification of histone tails, including acetylation, methylation,
phosphorylation, ubiquitination, and sumoylation, all of which regulate the degree of gene
expression33,

34

. The acetylation status of chromatin is determined by the dynamic

opposing functions of histone acetyl-transferases (HAT) and histone deacetylases (HDAC).
HAT add acetyl-groups to histones and create a hyperacetylated chromatin environment
which is associated with gene activation33, 34. HDAC remove acetyl-groups resulting in a
condensed chromatin structure which is associated with gene repression33, 34. Additionally,
HAT and HDAC also add/remove acetyl-groups to/from the lysine residues of non-histone
proteins38. To date, eighteen human HDAC have been identified and they are grouped into
four classes based on their sequence homology to yeast HDAC: Class I (HDAC 1, 2, 3 and
8), Class II (HDAC 4, 5, 6, 7, 9 and 10), Class III (SIRT 1-7), and Class IV (HDAC11)38, 145.
HDAC inhibitors (HDACi) are chemical HDAC modulators which interact with HDAC
and inhibit their activity with distinct potency and specificity38, 145-147. Initially studied as
anti-cancer agents, HDACi have been shown to promote cell differentiation, growth arrest,
apoptosis and senescence in cancer cells38, 145, 148. Further studies revealed that HDACi
have pleiotropic effects on other cell types. HDACi have been shown to inhibit vascular
smooth muscle cell (SMC) proliferation and prevent mechanically induced SMC
migration149,

150

. Additional evidence suggests an antithrombotic role of HDACi in

suppressing tissue factor expression in endothelial cells and monocytes151. HDACi have
also been shown to block inflammatory cytokine production in macrophages and dendritic
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cells152,

153

. Additionally, treatment with HDACi enhanced the pool of beta cells and

protected beta cells from cytokine induced cell death154, 155.
Nuclear receptors (NR) function as key transcriptional regulators of gene expression.
They share structurally conserved domains including N-terminal trans-activation domain,
central DNA binding domain and C-terminal ligand binding domain. In addition to
ligand-activated NR such as peroxisome proliferator-activated receptors (PPAR) and liver
X receptors (LXR), a group of orphan NR has been demonstrated to function as
ligand-independent NR. The primary mechanism by which NR regulate gene expression
is through recognizing and binding to their consensus response elements on target
promoters. The transcription complex initiated by NR binding further requires
HAT/HDAC activities to activate/silence gene transcription. cAMP response element
binding protein (CREB)-binding protein (CBP) and its homolog p300 are well
characterized transcription co-activators and their HAT activities are essential for
NR-dependent trans-activation156, 157. Nuclear receptor co-repressors (NCoR) have been
shown to interact with HDAC3 to silence NR target gene expression in the absence of
ligand binding158. In addition, the expression level of NR is also controlled by epigenetic
regulation. For instance, DNA hypermethylation within the promoter region plays a
fundamental role in silencing the expression of estrogen receptor alpha (ERα) and
androgen receptor (AR)159. Furthermore, the acetylation status of NR is also regulated by
HAT and HDAC, which influence NR ligand sensitivity and transcriptional activity159.
The neuron-derived orphan receptor 1 (NOR1) belongs to the ligand-independent
NR4A subfamily, a group of nuclear receptors which have been demonstrated to function
as immediate/early response genes. Transcriptional activity of the NR4A NR is dependent
on their expression level and post-translational modifications. Members of the NR4A
subfamily, including Nur77 (NR4A1), Nurr1 (NR4A2) and NOR1 (NR4A3), can be
induced by a wide range of physiological/pathological signals in different tissues52, 160.
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This induction often involves de novo RNA synthesis through transcriptional activation of
the NR4A promoters. In addition, NR4A orphan receptors are also subjected to
phosphorylation, sumoylation and acetylation modifications, which could affect their
transcriptional activity63,

68, 161

. We have previously demonstrated that NOR1 plays a

mitogenic role in vascular SMC, and NOR1 deficiency suppresses SMC proliferation and
decreases neointima formation61, 94, 95. A key biological event regulating mitogen-induced
NOR1 expression is CREB phosphorylation and the recruitment of phospho-CREB to the
consensus cAMP response elements (CRE) in the NOR1 promoter94, 106, 162. However, it
remains unknown whether phospho-CREB modifies the chromatin architecture at the
NOR1 promoter. In this study, we demonstrate that HDAC inhibition and platelet-derived
growth factor (PDGF) synergistically up-regulate NOR1 expression in SMC through
modifying the histone acetylation status of chromatin in the NOR1 promoter.
3.3. Materials and Methods
Cell culture
Rat aortic smooth muscle cells (RASMC) were purchased from Lonza and
maintained in DMEM supplemented with 10 % FBS. RASMC were starved in 0.01 %
FBS DMEM for 48 hours when they were 70 % confluent. Quiescent cells were
pretreated with Scriptaid (Sigma) (2 µg/ml) for 30 min and stimulated with rat PDGF-BB
(R & D Systems) (25 ng/ml) for indicated time points. For mRNA stability assays,
actinomycin D (Sigma) (10 µg/ml) was added to cell cultures to inhibit mRNA
transcription. For protein stability assays, cycloheximide (Sigma) (10 µg/ml) was added
to cell cultures to inhibit protein synthesis.
Quantitative real-time RT-PCR
Total RNA was isolated using TRIzol® (Invitrogen) and reverse transcribed into
cDNA using SuperScript II (Invitrogen). RNA expression levels of target genes were
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quantified using an iQTM SYBR Green Supermix (BioRad). Primers used in this study are
listed:

NOR1,

forward:

5’-CAGCAGCTGCGAACTCAA-3’;

5’-CGGTGTAGAAGGCGGAGA-3’;

HDAC1,

5’-CCATCAAAGGACATGCCAAGT-3’;
HDAC2,

5’-CGGCAAGAAGAAAGTGTGCTACT-3’;

forward:

HDAC3,

reverse:

forward:
reverse:

5’-ATGAGTCATCCGGATCCTATGG-3’;

RPL13A,

forward:
reverse:

5’-CGAGCGACATTACGGATGGT-3’;

5’-GCACCCGCATCGAGAATC-3’;

reverse:

forward:

5’-TGGACACTGGGTGCATGGT-3’;

5’GTACGCTGTGAGGGCATCAA-3’;

reverse:

5’-CTCGAGACGGGTTGGTGTTC-3’. PCR reactions were performed on an iCycler
(BioRad) using the following PCR cycles: 1 cycle of 95 °C 10 min; 40 cycles of 95 °C 30
sec, 55 °C 30 sec, 72 °C 30 sec; 1 cycle of a final extension at 72°C for 10 min. Each
sample was analyzed in triplicate and normalized to expression values of the
house-keeping gene RPL13A. Data were calculated using the 2-∆∆CT method137.
Western blotting
Western blotting was performed as previously described using antibodies against
NOR1 (R & D Systems), phospho-Ser133 CREB (Cell Signaling), CREB (Cell Signaling)
and GAPDH (FL 335) (Santa Cruz)94, 163.
Plasmids, transient transfections and luciferase Assay
The NOR1 promoter constructs have previously been described94. RASMC were
transiently transfected with 2 µg NOR1 promoter constructs for 6 hours using
lipofectamine (Invitrogen) in OPTI-MEM. Following transfection, cells were starved in
0.4% FBS DMEM and stimulated with scriptaid (2 µg/ml) for overnight. Luciferase
activities were analyzed using a Dual Luciferase Reporter Assay (Promega). Transfection
efficiency was normalized to renilla luciferase activities generated by cotransfection of
pRL-null-renilla.

72

Chromatin immunoprecipitation (ChIP) assays
ChIP assays were performed using the MAGnifyTM Chromatin Immunoprecipitation
System (Invitrogen) according to the manufacturer's instructions. Briefly, quiescent
RASMC were pre-treated with scriptaid (2 µg/ml) for 30 min and stimulated with PDGF
(25 ng/ml) for indicated time points. Sheared chromatin was immunoprecipitated using
antibodies against phospho-Ser133 CREB (Cell Signaling), AcH3K9 (Cell Signaling).
Target DNA product was amplified by PCR using primer pairs covering the three CRE
consensus sequences between -79 and -46 in the NOR1 promoter: forward,
5’-ACACACACCCTCGCACAC-3’; reverse, 5’-TCGGCACGTCATTTATGC-3’.
siRNA-mediated HDAC1-3 knockdown
siRNA experiments were performed using the SMARTpool technology (Dharmacon
RNA Technologies), which provides a mix of four different proprietary siRNAs specific
for the target gene. RASMC were transfected with HDAC1, HDAC2, HDAC3 or
scrambled siRNA (50 nM) using LipofectamineTM RNAiMAX (Invitrogen) for 6 hours.
Following transfection, cells were recovered in growth media overnight and starved in
0.01 % FBS DMEM for 48 hours, which was followed by stimulation with PDGF (25
ng/ml) for 6 hours.
Statistical analysis
Results were represented as means ± SEM. Unpaired Student’s t-test was utilized to
compare the means between two independent groups on a single variable. One-way or
Two-way ANOVA was used to compare groups. P values < 0.05 were considered to be
statistically significant.
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3.4. Results
NOR1 expression is enhanced by HDAC inhibitor Scriptaid in vascular SMC
To investigate the epigenetic regulation of NOR1 expression by histone acetylation,
we employed the HDACi Scriptaid. Scriptaid is a hydroxamic acid-containing HDACi
and has been reported to increase histone acetylation with low cytotoxicity164.
Pre-treatment with Scriptaid (2 µg/ml) potentiated NOR1 mRNA and protein expression
in response to PDGF (25 ng/ml) in vascular SMC. This effect was more apparent at the
later time point after PDGF stimulation (Figure 3.1A and B). Scriptaid alone also induced
NOR1 mRNA expression in quiescent vascular SMC, while control vehicle (DMSO) did
not have any effect, which indicates that HDAC activity is required to suppress NOR1
expression in the quiescent SMC (Figure 3.1C). However, Scriptaid treatment without
mitogenic stimulation only induced modest NOR1 expression compared to co-stimulation
with PDGF (Figure 3.1A and C). Collectively, these experiments suggest that cooperation
between mitogenic stimulation and hyperacetylation is important for maximal and
sustained NOR1 expression in vascular SMC.
siRNA-mediated knockdown of HDAC3 expression increases PDGF-induced NOR1
mRNA expression
Scriptaid functions as a pan-HDAC inhibitor, primarily targeting to Class I and Class
II HDACs. In order to investigate which HDAC regulates NOR1 mRNA expression,
vascular SMC were transiently transfected with siRNA against HDAC1, HDAC2 and
HDAC3 followed by PDGF stimulation. siRNA mediated knockdown of HDAC1-3 was
confirmed by quantitative RT-PCR (Figure 3.2A). Acute knockdown of HDAC3
significantly enhanced NOR1 mRNA expression at the basal level and after PDGF
stimulation, while HDAC1 or HDAC2 knockdown had no effect on NOR1 mRNA
expression (Figure 3.2B). Therefore, these experiments indicate that the HDACi Scriptaid
increases NOR1 mRNA expression through the regulation of HDAC3.
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Scriptaid increases NOR1 promoter activity without affecting NOR1 transcript
stability
mRNA accumulation is generally due to transcription activation, transcript
stabilization or both. To understand the mechanism by which NOR1 mRNA is increased
by HDAC inhibition, NOR1 promoter activity was first analyzed. We performed transient
transfection assays with reporter constructs driven by a 1.7kb NOR1 promoter and
demonstrated that Scriptaid increased NOR1 promoter activity in vascular SMC (Figure
3.3A). In order to analyze the effect of Scriptaid on NOR1 mRNA stability, vascular
SMC were pre-treated with Scriptaid or DMSO as control and followed by PDGF
stimulation for 2 hours to induce NOR1 mRNA accumulation. Actinomycin D (10 µg/ml)
was then added to cell cultures to inhibit mRNA transcription. As depicted in Figure 3.3B,
Scriptaid treatment did not have any effect on NOR1 mRNA stability. In summary, these
two experiments demonstrate that Scriptaid increases NOR1 mRNA expression by
activating NOR1 transcription.
Scriptaid enhances CREB phosphorylation and the recruitment of phospho-CREB
to its binding sites in the NOR1 promoter
We next continued to investigate the mechanisms by which Scriptaid activates
NOR1 transcription. We have previously demonstrated that CREB phosphorylation and
the recruitment of phospho-CREB to the NOR1 promoter are required for NOR1
transcription activation in response to PDGF94. Therefore, CREB phosphorylation was
analyzed. Interestingly, Scriptaid alone rapidly induced CREB phosphorylation within 30
min pre-treatment, although this effect was modest compared to PDGF stimulation
(Figure 3.4A). As expected, PDGF-induced CREB phosphorylation was strongly
enhanced by Scriptaid at each time point of this experiment (Figure 3.4A), which may
account for the augmented NOR1 mRNA expression with scriptaid pre-treatment (Figure
3.1A).
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HDAC inhibition has been demonstrated to increase histone acetylation which is
associated with chromatin decondensation and gene activation34, 38. To test this possibility,
histone acetylation in the NOR1 promoter region that contains the CRE sites was
analyzed by ChIP assays. Increased H3-lysine9 acetylation (AcH3K9) has been shown to
correlate with gene activation33. Analyses with antibodies against AcH3K9 demonstrated
that Scriptaid alone increased histone acetylation at the CRE binding sites in the NOR1
promoter (Figure 3.4B). This increased histone acetylation caused a corresponding
increase in the binding of phospho-CREB to the same region in the NOR1 promoter
(Figure 3.4C). As expected, Scriptaid pre-treatment further enhanced PDGF-induced
histone H3 acetylation and phospho-CREB recruitment at the CRE sites in the NOR1
promoter (Figure 3.4B and C). Collectively, these findings suggest that HDAC inhibition
by itself can increase phospho-CREB binding to the NOR1 promoter; however, upstream
signaling induced by mitogenic stimulation is required for further chromatin
decondensation and phospho-CREB enrichment, which ensures maximal NOR1
transcription.
HDAC inhibitor Scriptaid increases NOR1 protein stability
Post-translational modification of NR by acetylation and deacetylation has been
demonstrated to regulate NR stability, ligand binding sensitivity and transcription
activity159,

161, 165, 166

. Here we demonstrate that pre-treatment with HDACi Scriptaid

increases NOR1 protein half-life in response to PDGF stimulation (Figure 3.5A and B).
Collectively, HDACi Scriptaid enhances NOR1 expression at both the transcriptional and
post-translational levels.
3.5. Discussion
The complex initiated by the interaction of NR with co-activators/co-repressors also
involves histone modifier proteins facilitating gene activation and silencing167. In

76

addition to regulating chromatin dynamics, NR themselves are also subjected to the
control by histone modifier proteins159. The transcriptional activity of NOR1 is primarily
determined at the expression level and by post-translational modifications160. NOR1 has
previously been demonstrated to mediate mitogenic signaling in vascular SMC and its
deficiency suppresses SMC proliferation93-95. In the present study, we demonstrate that
NOR1 is induced, although modestly, by HDACi Scriptaid in vascular SMC. HDAC
inhibition and mitogenic stimuli have a synergistic effect on activating NOR1
transcription by increasing CREB phosphorylation and the recruitment of phospho-CREB
to the NOR1 promoter. Finally, we demonstrate that NOR1 protein stability is increased
by HDAC inhibition. Therefore, our findings provide an additional layer of regulation by
which mitogens regulate NOR1 expression.
The normal medial SMC proliferate at a very low rate28. However, in response to
mitogenic signals, SMC switch to a proliferative phenotype contributing to the
development and progression of vascular diseases, such as atherosclerosis/restenosis28, 168.
NOR1 has previously been demonstrated to be induced by PDGF in quiescent SMC, and
its deficiency reduces SMC proliferation and neointima formation in a murine model of
endothelium denudation94. In the present study, HDAC inhibition induces NOR1
expression in quiescent SMC, suggesting that HDAC activity is required to prevent this
mitogenic transcription factor from inappropriate activation in the normal vasculature.
This effect was confirmed by transient transfection assays in which Scriptaid treatment
increased NOR1 promoter activity in SMC. (Fig. 3A). Contrary to our findings,
cAMP-activated NOR1 expression in PC12 cells has been reported to be suppressed by
TSA, an HDAC inhibitor sharing a similar structure with Scriptaid, which might be due
to the different cell line or stimulus used in that study169. In support of our findings,
another NR4A member Nur77 has been reported to be induced by TSA169. In thymocytes,
HDAC7 suppresses Nur77 expression which is increased by treatment with pan-HDAC

77

inhibitors170. Additionally, HDAC1 has been documented to be recruited to the Nurr1
promoter to repress Nurr1 expression in unstimulated cells171. Collectively, these findings
suggest that HDAC may serve as a general regulator of NR4A nuclear receptors to ensure
their appropriate expression. Furthermore, it is worth noting that Scriptaid induced NOR1
expression is much lower than co-stimulation with PDGF, linking the extracellular
signals and chromatin modification in inducing NOR1 expression in SMC.
Previous studies point to a critical role of CREB activation in inducing NOR1
expression in vascular SMC94, hepatocytes69 and adipocytes77, demonstrating NOR1 as a
CREB-responsive gene. The interaction of HDAC1/2 with phosphatase 1 (PP1) has been
implicated in repressing cAMP-activated CREB-responsive gene expression by
cooperatively mediating CREB dephosphorylation and histone deacetylation in the target
promoters171. To test which HDAC is involved in controlling NOR1 promoter activation,
we employed siRNA technology to knockdown HDAC1, HDAC2 or HDAC3 in SMC.
Surprisingly, HDAC1 or HDAC2 knockdown did not affect PDGF-induced NOR1
mRNA expression. By contrast, HDAC3 knockdown results in more than a 2-fold
increase in NOR1 expression at both the basal level and after PDGF stimulation. These
two studies suggest that the specificity of HDAC recruitment to a CREB target gene is
influenced by the local chromatin structure within the promoter region. In support of our
observation, HDAC6 has been shown to be recruited to the promoter of glucocorticoid
receptor (GR) and repress GR expression by uncoupling the CREB responses172.
As previously mentioned, NOR1 is a CREB responsive gene69,

77, 94

. We next

analyzed CREB phosphorylation and found that Scriptaid alone increased CREB
phosphorylation and co-stimulation with PDGF further enhanced CREB phosphorylation
at each time point examined in the Figure 3.4A. This observation is consistent with
previous findings that HDACi TSA sustained CREB phosphorylation

173

. However, TSA

failed to increase CREB phosphorylation and gene transcription over the early time
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points in that study, suggesting that cAMP activation is capable of inducing the maximal
amount of CREB phosphorylation. Therefore, these distinct effects of HDAC inhibition
in promoting CREB target gene transcription indicate that PDGF alone is insufficient to
lead to maximal CREB phosphorylation and gene activation. Our observation confirmed
previous findings that growth factors or stress signals are less effective in promoting
CREB target gene transcription compared to cAMP agonist174, 175.
HDAC inhibition has been demonstrated to increase histone acetylation which is
associated with gene activation34, 38. In ChIP assays, HDACi scriptaid increased histone
acetylation at the CRE sites within the NOR1 promoter, resulting in increased recruitment
of phospho-CREB (Figure 4B and 4C). Scriptaid alone increased histone H3 acetylation
and phospho-CREB recruitment to levels comparable to PDGF stimulation alone.
However, PDGF co-stimulation after Scriptaid treatment only modestly increased histone
acetylation, which indicates that HDAC inhibition alone maximally loosened chromatin.
By contrast, phospho-CREB recruitment was highly increased by PDGF co-stimulation
after scriptaid treatment. This indicates that although upstream signaling did not further
relax chromatin structure, it is necessary for the enrichment of phospho-CREB
availability in the nucleus. These experiments reinforce the necessity of upstream
signaling for maximal CREB phosphorylation, recruitment and NOR1 transcription.
HDAC substrates include a large amount of non-histone proteins and acetylation of
these non-histone proteins has been shown to modulate their functionality and protein
stability38. Many nuclear receptors are subjected to acetylation, which regulates their
stability, ligand sensitivity and trans-activation ability159. Finally, NOR1 stability was
demonstrated to be enhanced by scriptaid, indicating NOR1 as a HDAC substrate.
In summary, our findings suggest that HDAC inhibition increases NOR1 expression
at multiple levels, including gene transcription and protein stability. HDACi have been
suggested to suppress smooth muscle cell proliferation and migration149, 150, serving as
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potential therapeutic targets for treating vascular diseases driven by SMC proliferation.
NOR1 has previously been demonstrated as a mitogenic transcription factor promoting
SMC cell proliferation and survival160. Therefore, our studies may provide a potential
target for further sensitizing smooth muscle cells to HDAC inhibition.
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Figure 3.1. NOR1 expression is enhanced by HDACi Scriptaid in VSMC
(A-B) Quiescent RASMC were pretreated with Scriptaid (2 µg/ml) or DMSO for 30 min,
and subsequently stimulated with PDGF (25 ng/ml). NOR1 mRNA (A) and protein
expression (B) were analyzed at the indicated time points. mRNA expression was
normalized to RPL13A and expressed as mean ±

SEM fold increase over

DMSO-untreated cells (*P < 0.05 vs. untreated; #P < 0.05 vs. DMSO). Cohybridization for
GAPDH was performed to assess equal loading. The autoradiograms are representative of
three independently performed experiments. (C) Quiescent RASMC were stimulated with
Scriptaid (2 µg/ml) or DMSO for 0.5, 2, 6, 12 and 24 hr for NOR1 mRNA analyses. mRNA
expression was normalized to RPL13A and expressed as mean ± SEM fold increase over
untreated (UT) cells (*P < 0.05 vs. UT). Experiments were repeated at least three times in
duplicate with different cell preparations.
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Figure

3.2.

siRNA-mediated knockdown

of

HDAC3

expression increases

PDGF-induced NOR1 mRNA expression
(A-B) RASMC were transiently transfected with HDAC1, HDAC2, HDAC3 or scrambled
(scr) siRNA (50 nM) for 6 hours, and recovered in growth media overnight. Transfected
cells were starved in 0.01% FBS DMEM for 48 hours and stimulated with PDGF (25 ng/ml)
or vehicle (PBS) for 6 hours for mRNA analyses. The expression of HDAC1, HDAC2,
HDAC3 and NOR1 was normalized to RPL13A and expressed as mean ± SEM fold
increase over scr-siRNA-transfected vehicle-treated cells (*P < 0.05 vs. vehicle, #p < 0.05
vs. scr-siRNA).
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Figure 3.3. Scriptaid increases NOR1 promoter activity without affecting NOR1
transcript stability
(A) RASMC were transiently transfected with a luciferase reporter construct (2 µg) driven
by a 1.7kb NOR1 promoter and stimulated with DMSO or Scriptaid (2 µg/ml) overnight.
Protein lysate was collected and analyzed for luciferase activities. Data were normalized to
renilla luciferase activities and presented as mean ± SEM from three independently
performed experiments (*p < 0.05 vs. DMSO). (B) Quiescent RASMC were pretreated
with Scriptaid (2 µg/ml) or DMSO for 30 min and subsequently stimulated with PDGF (25
ng/ml) for 2 hours. Actinomycin D (10 µg/ml) was added to inhibit transcription and
mRNA was collected at the indicated time points. NOR1 mRNA expression was
normalized to RPL13A from three independent experiments. Data are expressed as mean ±
SEM fold increase over the samples stimulated with PDGF for 2 hr. N.S. indicates that no
statistical significance was detected between DMSO and Scriptaid treatments.
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Figure 3.4. Scriptaid enhances CREB phosphorylation and the recruitment of
phospho-CREB to its binding sites in the NOR1 promoter
(A) Quiescent RASMC were pretreated with Scriptaid (2 µg/ml) or DMSO for 30 min and
subsequently stimulated with PDGF (25 ng/ml) for 0.5, 1 and 3 hr for protein analyses.
Cohybridization for total CREB was performed to assess equal loading. The
autoradiograms are representative of three independently performed experiments. (B-C)
Quiescent RASMC were pretreated with Scriptaid (2 µg/ml) or DMSO for 30 min and
subsequently stimulated with PDGF (25 ng/ml) for 1 hr for ChIP assays. Chromatin
complexes were immunoprecipitated with antibodies against phospho-S133 CREB,
AcH3K9, and species-matched IgG. PCR products were amplified using primers covering
the CRE sites from -79 bp to -46 bp in the NOR1 promoter. The agarose gels shown are
representative of three independently performed experiments.
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Figure 3.5. HDAC inhibitor Scriptaid increases NOR1 protein stability
(A-B) Quiescent RASMC were pretreated with Scriptaid (2 µg/ml) or DMSO for 30 min
and subsequently stimulated with PDGF (25 ng/ml) for 6 hours. Cycloheximide (CHX, 10
µg/ml) was added to inhibit protein synthesis and protein was collected at the indicated
time points. (A) The autoradiograms are representative of three independently performed
experiments. Cohybridization for GAPDH was performed to assess equal loading. (B)
Densitometric quantification of NOR1 expression was performed from three independent
experiments and normalized to GAPDH expression. Results are expressed as mean ± SEM
fold increase over samples treated with PDGF for 6 hr. (*p < 0.05 vs. PDGF 6 hr, # p < 0.05
vs. DMSO).
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Chapter four: General discussion
4.1. Discussion
4.1.1. Summary
The primary goal of this study is to understand the role of the NR4A3 orphan
nuclear receptor (NR) NOR1 in the development of atherosclerosis. We demonstrate that
NOR1 is highly expressed in human atherosclerotic lesions, while NOR1 expression is
absent in the normal vasculature. In advanced atherosclerotic lesions, NOR1 expression
co-localizes with endothelial and sub-endothelial cells. Following experiments performed
in this study focus on the regulation of NOR1 expression in endothelial cells and smooth
muscle cells, and the significance of NOR1 in the development of atherosclerosis. In
endothelial cells we demonstrate that NOR1 expression is rapidly and potently induced
by several pro-inflammatory factors through an NF-κB dependent signaling pathway.
Functional analyses point to a previously unrecognized role of NOR1 in promoting
monocyte adhesion by increasing VCAM-1 and ICAM-1 expression in endothelial cells.
Consistently,

NOR1

deficiency

decreased

atherosclerosis

formation

in

a

hypercholesterolemia mouse model. Quantitative macrophage staining reveals reduced
macrophage accumulation in the NOR1-deficient atherosclerotic lesions. In smooth
muscle cells (SMC), NOR1 expression is induced by mitogenic stimulation, and this
effect is further enhanced by HDAC inhibition. Mechanistic studies demonstrate that
HDAC inhibition increases NOR1 expression by promoting NOR1 mRNA transcription
and protein stability. In summary, this study has demonstrated that NOR1 acts as an
atherogenic transcriptional regulator promoting monocyte-endothelial cell adhesion, and
has provided mechanisms for the epigenetic control of mitogen-induced NOR1
expression in SMC. In the following discussion of my dissertation, I will further discuss
the role of NOR1 in vascular diseases, focusing on the concepts not mentioned in
previous chapters as well as the relationship to its NR4A siblings Nur77 and Nurr1.
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Finally, I will discuss some of my own understandings regarding the significance of NRs
in the prevention of cardiovascular diseases.
4.1.2. The role of NOR1 in endothelial cells
Activation of several NR has been reported in endothelial cells176-185. PPARα and
PPARγ are the best studied NRs in endothelial cells and PPAR activation has been
implicated in endothelial cell activation, proliferation and survival176-181, 183. In addition to
ligand-activated nuclear receptors177, 186, an increasing number of studies have pointed to
the significance of orphan NR, including COUP-TFII185, retinoic acid receptor
(RAR)-related orphan nuclear receptor α (RORα)

182

and NR4A NR160, in regulating

endothelial cell proliferation and inflammation.
In Chapter two, we demonstrate in endothelial cells that NOR1 is induced by
inflammatory cytokines and enhances monocyte adhesion by increasing VCAM-1 and
ICAM-1 expression. We performed transient transfection assays and ChIP assays
showing that NOR1 activates VCAM-1 transcription by directly binding to the NBRE
site in the NOR1 promoter. However, mutations introduced into the NBRE site did not
completely abolish the VCAM-1 promoter activity induced by NOR1 over-expression
(Figure 2.6B), indicating that other transcriptional regulators may be involved in
VCAM-1 trans-activation.
Several studies have revealed that NR also function as co-regulators modulating
gene expression through interacting with other transcription factors187, 188. Both NF-κB
and AP-1 are critical transcription factors regulating VCAM-1 expression during
endothelial activation/dysfunction189-191. Therefore, it is intriguing to understand whether
NOR1

promotes

NF-κB/AP-1-dependent

transcription

activation.

Preliminary

experiments were performed in endothelial cells by transiently transfecting luciferase
reporter constructs driven by multiple NF-κB/AP-1 response elements. Interestingly,

92

NOR1 over-expression increased the promoter activity of plasmids driven by NF-κB
response elements, while no induction was observed on plasmids driven by AP-1
response elements (Figure 4.1A and B). NF-κB proteins are ubiquitously expressed in
many cell types and they are sequestered in the cytoplasm by binding to the inhibitor of
NF-κB (IκB) in unstimulated cells. NF-κB is activated by a series of phosphorylation
reactions which ultimately lead to IκB degradation and release of NF-κB to the
nucleus192. We first analyzed whether NOR1 expression induces NF-κB nuclear
translocation in endothelial cells. As described in Figure 4.1C, NOR1 over-expression
exhibited no apparent effect on NF-κB nuclear enrichment when evaluated by p65
immunostaining. Another possibility relies on the direct interaction between NOR1 and
NF-κB. Immunoprecipitation (IP) assays demonstrated an interaction between NOR1 and
NF-κB p65 (Figure 4.1D), thus indicating that NOR1 may interact with NF-κB in the
nucleus and stabilize the binding of NF-κB to its promoters. Future experiments need to
be performed to demonstrate the co-recruitment of NOR1 to the NF-κB binding sites in
the VCAM-1 promoter. In support of our observation, AP-1 transcription factors c-Fos
and c-Jun have been shown to interact with NF-κB and enhance VCAM-1
trans-activation in endothelial cells193.
By contrast, other NR, such as PPARγ, estrogen receptor (ER), and glucocorticoid
receptor (GR), have been implicated in the repression of VCAM-1 expression in
endothelial cells by suppressing NF-κB/AP-1 dependent trans-activation194, 195. Nur77, an
NR4A orphan NR sharing high protein sequence homology with NOR1, has recently
been shown to repress VCAM-1 and ICAM-1 expression in endothelial cells by
increasing the expression of NF-κB inhibitor IκBα104. This study suggests a novel
mechanism that NR repress adhesion molecule expression by interfering with NF-κB
upstream signaling pathway. However, we did not observe any evidence of increased
IκBα expression by NOR1 in our study (data not shown). These seemingly opposing
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findings suggest that Nur77 and NOR1 may interact with different co-factors to regulate
target gene expression.
In addition, PPARα has been shown to interfere with AP-1/NF-κB-dependent IL-6
transcription by physically interacting with c-Jun and p65 in vascular SMC196. Activation
of Liver X receptors (LXR) suppresses matrix metalloproteinase (MMP)-9 expression
through antagonizing the NF-κB signaling pathway in macrophages197. Recently, NR4A
nuclear receptor Nurr1 was shown to dock to NF-κB-p65 resulting in NF-κB clearance
and trans-repression of inflammatory gene expression in microglia and astrocytes60.
Therefore, the involvement of NR in NF-κB transcription complexes likely serves as a
general mechanism, by which NR regulate transcriptional responses to inflammatory
signaling. While most studies point to a NR-mediated trans-repression mechanism, our
findings have provided evidence that NF-κB target gene expression could be modulated
through a trans-activation mechanism.
4.1.3. The role of NOR1 in vascular smooth muscle cells
Atherosclerosis progression is associated with SMC migration into the arterial intima.
Intimal SMC are characterized by an accelerated proliferation rate and greater synthetic
capability, while normal medial SMC exhibit a contractile phenotype maintaining a
quiescent state. HDAC inhibitors (HDACi) have been used in clinical trials as novel
anticancer agents due to their beneficial effect on promoting cell differentiation, growth
arrest, and apoptosis of tumor cells145, 148. In addition, recent discovery has shown that
HDACi exhibit beneficial effects in vascular cells. HDAC inhibition represses vascular
SMC proliferation and prevents mechanically induced vascular SMC migration149, 150, 164.
Consistent with these observations, our preliminary data show that HDACi Scriptaid
increases apoptosis in quiescent SMC (Figure 4.2).
We have previously demonstrated that NOR1 plays a critical role in promoting SMC
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survival and mitogen-induced proliferation95. In Chapter three, we demonstrate that
HDACi Scriptaid and PDGF synergistically increase NOR1 expression in SMC.
Therefore, Scriptaid-induced NOR1 expression may impair the efficacy of HDAC
inhibition and attenuate HDACi-induced SMC apoptosis/growth arrest. In fact, HDACi
resistance has been previously investigated and the underlying mechanisms involve
up-regulation of antioxidant pathways and increased expression of anti-apoptotic
proteins148, 198. Experiments in which Scriptaid-induced apoptosis is compared between
NOR1 wildtype and deficient SMC may provide some insight on the role of NOR1 in
HDACi resistance. Silencing or suppressing NOR1 expression may increase SMC
sensitivity to HDACi induced apoptosis/growth arrest, hence potentiating the efficacy of
HDACi for treating vascular diseases primarily driven by SMC proliferation.
Statins, which are used in clinical trials for treating cardiovascular diseases by
reducing plasma LDL-cholesterol levels, have shown some promise by reducing
LDL/hypercholesterolemia-induced NOR1 expression in SMC and aortae107. More
interestingly, statins have recently been demonstrated as novel HDAC inhibitors199.
Computational modeling and immunoprecipitation assays provided evidence suggesting
that the carboxylic acid moiety of statins directly targets the catalytic site of HDAC
thereby inhibiting the activities of HDAC1-3. These findings challenged our observations
in Chapter three and raised the question of how statins inhibit HDAC activity yet also
repress NOR1 expression. One possible explanation resides in the disrupted CREB
phosphorylation by statins. Although statins can increase histone acetylation creating
looser chromatin structure, the lack of phospho-CREB may account for the repression of
NOR1 expression. This is reminiscent of our observation that HDAC inhibition alone
only induces NOR1 expression modestly, while maximal NOR1 expression relies on the
abundance of phospho-CREB. These seemingly contradictory findings emphasize the
importance and necessity to investigate the epigenetic control of NOR1 expression.
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4.1.4. The role of NOR1 in atherosclerosis development
The expression of NR4A nuclear receptors has been implicated in vascular diseases
including atherosclerosis, restenosis and vascular remodeling160, 200. In vivo studies show
that Nur77 or Nurr1 over-expression in SMC decreases lesion formation in a carotid
artery ligation model by restricting SMC proliferation91,

201

. This repressive effect is

potentiated by 6-mercaptopurine, an antineoplastic agent mediating the activation of
NR4A nuclear receptors, in a mouse model of cuff-induced neointima formation202.
Nur77 over-expression in SMC also protects against vascular outward remodeling by
reducing macrophage accumulation and MMP expression203. Additionally, NR4A
receptors have been shown to repress the expression of inflammatory cytokines and lipid
loading in macrophages97. Together, these studies point to a protective role of Nur77 and
Nurr1 in reducing vascular SMC proliferation and macrophage inflammation.
Conversely, opposing regulatory effects of NR4A receptors have been suggested by
other studies. Nur77 over-expression increases inflammatory signaling in macrophages
and endothelial cells99, 116. In addition, NOR1 promotes SMC survival and proliferation
and its deficiency reduces neointima formation in a murine endothelium denudation
model95. Nonetheless, direct evidence is still lacking with regard to the role of NR4A
receptors in atherosclerosis development.
Based on our findings in Chapters two and three, NOR1 expression in endothelial
cells increases monocyte adhesion and mediates mitogen-induced cell proliferation in
smooth muscle cells. Hence, we hypothesized that NOR1 functions as an atherogenic
transcriptional regulator in the vascular wall. To investigate our hypothesis,
NOR1-/-apoE-/- mice were generated to create a hypercholesterolemia background to
study the role of NOR1 in atherosclerosis development. As expected, NOR1 deficiency
decreases atherosclerosis formation accompanied by reduced macrophage accumulation
in the sub-endothelial space.
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However, it is worth noting that NOR1 deficiency only partially blocked
atherosclerosis formation. Although macrophage accumulation is reduced in NOR1
deficient lesions, significant amount of macrophages are still readily detectable in the
arterial intima. One possible explanation may reside in the excessive leukocytosis in
NOR1 deficient mice (Figure 4.3A). The leukocytosis in NOR1-deficient mice is
primarily due to increased monocyte, lymphocyte, and granulocyte numbers in the
absence of changes in red blood cell counts. Studies have demonstrated that monocyte
recruitment is mediated by different adhesion molecules on the endothelial cell surface7.
As proposed in this study, NOR1 deficiency reduces monocyte adhesion via VCAM-1
and ICAM-1. However, the reduction of monocyte adhesion could be impaired due to
increased monocyte availability in the blood. In addition, a large amount of evidence
supports the presence of T lymphocytes and granulocytes in the atherosclerotic lesions,
which contributes to atherosclerosis development and progression17, 18, 204, 205. Increased
lymphocyte and granulocyte numbers may also account for the residual lesions seen in
the NOR1-deficient mice.
Our preliminary experiments also showed that NOR1-deficient leukocytes isolated
from the peritoneal cavity after thioglycollate injection are more susceptible to apoptosis
compared to NOR1 wildtype peritoneal cells (Figure 4.3B). This indicates that
NOR1-deficient leukocytes are defective in clearing exotoxins or surviving immune
insults. Recently, the concept inflammation resolution has drawn increasing attention and
has provided new insights in the treatment of atherosclerosis23. One key step in resolving
inflammation in atherosclerotic plaques is efferocytosis of apoptotic inflammatory cells23.
The major effectors of efferocytosis include macrophages and dendritic cells23. It is very
likely that NOR1-deficent macrophages/dendritic cells are less efficient in clearing
apoptotic/dead inflammatory cells in the vascular wall, which will ultimately result in the
accumulation of apoptotic macrophages and aggravation of inflammatory responses. For
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that reason, it would be helpful to analyze the efferecytosis ability of NOR1-deficient
monoyctes/macrophages and compare their viability in response to proatherogenic
stimuli.
In order to understand whether NOR1 deficiency results in increased macrophage
accumulation, several approaches may be considered. One experiment is bone marrow
transplantation, in which NOR1-deficient and wildtype bone marrow cells are
transplanted to lethally irradiated apoE-/- mice. Based on our hypothesis, mice
transplanted with NOR1-deficient bone marrow cells will develop more atherosclerosis
than mice transplanted with NOR1-wildtype bone marrow. However, bone marrow cells
are highly heterogeneous, consisting of hematopoietic stem cells and progenitor cells at
various differentiation stages. As an alternative, mice with tissue-specific NOR1
knockdown in the monocyte-macrophage lineage will serve as a better strategy.
Furthermore, mice with specific NOR1 knockdown in endothelial cells will confirm our
previous findings that NOR1 deficiency decreases atherosclerosis formation by blocking
monocyte adhesion. In summary, these studies will provide a better understanding of the
mechanisms by which NOR1 promotes atherosclerosis.
4.1.5. Implications for the prevention of cardiovascular diseases
Numerous studies have been performed in order to provide potential targets for the
prevention and treatment of cardiovascular diseases. Many nuclear receptors have shown
beneficial effects in the vasculature. The activation of PPARα by synthetic agonists
reduces cardiovascular disease by improving lipid homeostasis206. PPARγ, which was
originally used for increasing insulin sensitivity, also reduces a wide range of
cardiovascular risk factors, including inflammatory cytokines, adipokines and free fatty
acids207. LXR are key transcriptional regulators controlling cholesterol metabolism and
promoting reverse cholesterol transport in macrophages208. In vivo studies have shown
that activation of LXR plays a protective role in atherosclerosis development in mouse
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models208-211. In addition, estrogen receptors and glucocorticoid receptors have shown
some vasoprotective effects by repressing inflammatory signaling212, 213.
The activation/repression of NR by the binding of small molecules has proved
advantageous for the treatment of cardiovascular diseases. In this study, we demonstrate
that decreased NOR1 expression in the vasculature protects against atherosclerosis
development163. However, the lack of a typical ligand-binding pocket in the NOR1
protein considerably limits the possibility of using small molecules to suppress NOR1
transcriptional activity51. In addition, induced NOR1 expression in other tissues has been
shown to be indispensible for maintaining normal physiological functions69, 77, 78, 89. In
response to starvation, NOR1 increases gluconeogenesis in the liver69. In the skeletal
muscle, NOR1 enhances oxidative metabolism77 and glucose uptake78. NOR1 also plays
a critical role in regulating thermogenesis in the adipose tissue89. Furthermore, our
preliminary data showed that NOR1 deficiency resulted in an increase in the body weight
when NOR1+/+ and NOR1-/- mice were fed a chow diet (data not shown). Therefore,
unless tissue specific modulators are developed, NOR1 suppression by antagonists may
result in unpredictable side effects on the normal processes of metabolism.
These two challenges raise the question of the implications of our studies on the
role of NOR1 in atherosclerosis development. NOR1 can be induced by a variety of
cardiovascular risk factors, such as hypercholesterolemia and inflammatory cytokines160,
and plays an atherogenic role in the vascular wall. Therefore, a tight control on these risk
factors may reduce the possibility and magnitude of NOR1 induction and protect against
atherosclerosis. For example, fat constitutes an important component in our daily diet.
Dietary fat has a great impact on the plasma lipoprotein profile, which is a key factor in
mediating atherosclerosis development214. Long-chain saturated fatty acids (LC-SFA),
but not long-chain un-saturated fatty acids (LC-USFA) or short-chain fatty acids (SC-FA),
have been shown to activate NF-κB and promote inflammatory gene expression in
endothelial cells215,

216

. Our studies demonstrate NOR1 as an NF-κB target gene in
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endothelial cells, indicating that NOR1 is likely to be induced by LC-SFA163. In smooth
muscle cells, NOR1 can be induced by low density lipoprotein (LDL), a key risk factor in
the onset of atherosclerosis106. By contrast, USFAs tend to improve the lipoprotein profile
by decreasing LDL cholesterol levels214. Omega-3 fatty acids have been shown to repress
endothelial activation by reducing NF-κB activation217. Collectively, these studies
indicate that limiting the amount of LC-SFAs in the diet may provide beneficial effects
on reducing NOR1 expression in endothelial cells and smooth muscle cells. A diet with a
higher percentage of USFA will be favorable in reducing cardiovascular risk by
improving plasma lipoprotein profiles and thereby suppressing NOR1 expression in the
vascular wall.
4.2. Perspectives
As investigated and discussed in this study, the ligand-independent NR4A3 orphan
nuclear receptor NOR1 functions as an immediate early response gene. All cell types
participating in vascular diseases rapidly induce NOR1 expression in response to arterial
injury. Our in vivo studies using a murine hypercholesterolemia model demonstrate NOR1
as an atherogenic transcriptional regulator. Nevertheless, several key questions still need to
be answered. All the NR4A nuclear receptors bind to the same NBRE site, which is
indicative of functional redundancy among these NR4A members. However, deficiency of
any NR4A nuclear receptor is associated with an apparent phenotype (NOR1 deficiency
decreases atherosclerosis163, Nur77 deficiency impairs insulin sensitivity76, Nurr1
deficiency results in neonatal lethality218), demonstrating that each NR4A member has
specific functions which cannot be compensated by the other two siblings. In addition, an
intriguing question is what are the distinct roles of NOR1 in endothelial cells and
monocytes/macrophages with relevance to regulating atherosclerosis development?
Another important question for future investigation is how to reconcile the distinct
biological effects of NOR1 and Nur77/Nurr1 in vascular cells and the development of
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atherosclerosis? In order to answer these questions, a key emphasis of future research is to
identify NR4A target genes and define the genome-wide pattern of NR4A chromatin
occupancy. In addition, advances in understanding NR4A posttranslational modifications
and co-activator/co-repressor recruitment will help establish detailed transcriptional
networks by which NR4A receptors control vascular gene expression programs. Continued
investigation of these questions will provide new insights into how these NR4A receptors
participate in the processes of normal metabolism and the development of cardiovascular
diseases.
4.3. Conclusion
In this study, we have performed extensive studies and made substantial progress in
understanding the regulation of NOR1 expression in endothelial cells and smooth muscle
cells. We further identified VCAM-1 as a bona fide NOR1 target gene in endothelial cells.
In vivo studies using a murine model of hypercholesterolemia provide initial evidence
characterizing NOR1 as an atherogenic transcriptional regulator. Increased NOR1
expression in response to HDAC inhibition suggests NOR1 may contribute to HDACi
resistance in smooth muscle cells. Therefore, manipulation of NOR1 expression may
provide some insight into therapeutic treatment for vascular diseases such as
atherosclerosis and restenosis.
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Figure 4.1. NOR1 increases NF-κB-dependent transcription activation by
interacting with NF-κB p65 without affecting p65 translocation
(A-B) HUVEC were transiently transfected with luciferase reporter constructs (0.5 µg)
driven by multiple NF-κB/AP-1 response elements. Cells were co-transfected with NOR1
or GFP expression vector (0.5 µg) and recovered overnight following transfection. Protein
lysate was collected and analyzed for luciferase activities. Data were normalized to renilla
luciferase activities and presented as mean ± SEM (*p < 0.05 vs. pCMV-GFP). (C)
HUVEC were infected with 50 PFU Ad-CMV-NOR1 or Ad-CMV-Null as control. Infected
cells were immunostained for NF-κB p65. Images were acquired using confocal
microscopy (objective magnification x200). Stainings for p65 and DAPI were merged into
one image as indicated. (D) HEK293 cells were transiently transfected with NOR1 and
p65 over-expression vectors (2 µg) and recovered for 24 hours. Cell lysates were collected
and immunoprecipitated with an antibody against p65 (5 µg). Precipitates were subjected
to SDS–PAGE and immunoblotted with indicated antibodies.
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Figure 4.2. HDAC inhibition increases smooth muscle cell apoptosis
Quiescent human coronary smooth muscle cells were stimulated with Scriptaid (2 µg/ml)
or DMSO for 2 days. Cells were then collected and subjected to annexin V and propidium
iodide (PI) staining and apoptosis was quantified using fluorescence activated cell sorting
(FACS). Data are presented as mean ± SEM (*p < 0.05 vs. DMSO).
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Figure 4.3. NOR1 deficiency increases leukocytosis and leukocyte apoptosis in the
peritoneal cavity
(A) 6 NOR1+/+ and 6 NOR1-/- mice (8-12 weeks old) were used for this study. Blood was
drawn from the mouse retro-orbital sinus and blood cell count was assessed using a
Hemavet cell counter. Data were presented as mean ± SEM (*p < 0.05 vs. NOR1+/+). (B)
6 NOR1+/+ and 6 NOR1-/- mice (8-12 weeks old) were injected intraperitoneally with 3
ml thioglycollate media (3 %). 3 days after injection, peritoneal cells were isolated in 6 ml
PBS by peritoneal lavage and subjected to annexin V and PI staining. Apoptosis was
analyzed using fluorescence activated cell sorting (FACS). Data are presented as mean ±
SEM (*p < 0.05 vs. NOR1+/+).
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Appendices
Appendix A. Methods
1. Whole cell lysate collection and Western blotting
(1) Whole cell lysate collection


Perform each step on ice



Rinse the cell monolayer twice with ice-cold phosphate buffered saline (PBS)



Remove the remaining PBS completely



Add 100 µl/ 10 cm cell culture plate of 1x ice-cold lysis buffer (Cell Signaling)
containing 1 % protease inhibitor cocktail (Sigma)



Collect cells in a 1.5 ml eppendorf tube using cell lifters



Homogenize by vortexing and sitting in ice for 10 min



Centrifuge at 13,000 rpm, 4 °C for 15 min



Transfer the supernatant to a fresh tube, and proceed to the next step

(2) Protein concentration measurement


Measure protein concentration using the Bio-Rad DC Protein Assay Reagents
Package containing Reagents A, B and S



Prepare dilutions of Bovine Serum Albumin (BSA) Standard (2 mg/ml) in 1.5 ml
eppendorf tubes as follows:
Dilution

2 mg/ml BSA

25 µl

S1, 0 mg/ml



Distilled H2O

S2, 0.16 mg/ml

2 µl

23 µl

S3, 0.32 mg/ml

4 µl

21 µl

S4, 0.8 mg/ml

10 µl

15 µl

S5, 1.0 mg/ml

12.5 µl

12.5 µl

S6, 1.2 mg/ml

15 µl

10 µl

Prepare protein dilutions by adding 2.5 µl protein to 10 µl distilled H2O
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Prepare dye reagent by diluting 25 µl Reagent S in 1 ml Reagent A



Pipette 5 µl standards (S0-S6) and sample dilutions in duplicate to a 96 well plate



Pipette 25 µl dye reagent into each well



Pipette 200 µl Reagent B into each well



Measure absorbance at 595 nm using a microplate reader

(3) Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)








1x Electrode buffer
Tris Base

3.03 g

Glycine

14.4 g

SDS

1g

Distilled H2O

to 1 L

1x Transfer Buffer
Tris Base

4.64 g

Glycine

2.32 g

Methanol

160 ml

10 % SDS

3 ml

Distilled H2O

640 ml

Total

800 ml

10x TBS
Tris Base

24.2 g

NaCl

80 g

Adjust pH to 7.6 with HCl

~ 10 ml

Distilled H2O

To 1 L

1x TBST
10x TBS

100 ml

Tween-20

1 ml (0.1 %)

Distilled H2O

To 1 L
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Separating Gel, 7.5 %, 15 mm (for 2 gels)
Distilled H2O

6.8 ml

1.5 M Tris-HCl, pH 8.8

3.5 ml

10 % SDS

140 µl

30 % Acrylamide/Bis

3.5 ml

10 % Ammonium Persulfate (APS)

100 µl

TEMED

20 µl

Total

14 ml

Stacking Gel, 15 mm (for 3 gels)
Distilled H2O

5.5 ml

0.5 M Tris-HCl, pH 6.8

2.25 ml

10 % SDS

90 µl

30 % Acrylamide/Bis

1.2 ml

10 % Ammonium Persulfate (APS)

60 µl

TEMED

10 µl

Total

9 ml



Load 40 µg protein/ well



Run the gel at 50 V for 1 hour and switch to 100 V for 1.5 hours



Transfer proteins onto the nitrocellulose membrane (GE Healthcare Life Sciences)



Transfer proteins at 100 V for 2 hours

(4) Western blotting


Block the membrane in 5 % fat-free milk/ TBST buffer at room temperature (RT) for
1 hour



Add primary antibody (1:1000 v/v dilution) and incubate the membrane on shaker at
4 °C overnight



Rinse the membrane with 1x TBST for 5 min on shaker



Repeat the last step twice with fresh TBST
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Bind secondary antibody (1:2000 v/v dilution) in 5 % milk/ TBST buffer at RT for
1.5 hours



Rinse the membrane with 1x TBST for 5 min on shaker



Repeat the last step 4 times with fresh TBST



Visualize target proteins with autoradiography using Amersham ECLTM Western
Blotting Detection Reagents (GE Healthcare Life Sciences)

2. RNA isolation and Quantitative reverse transcription polymerase chain reaction
(RT-PCR)
(1) RNA isolation and RNA concentration measurement


Rinse the cell monolayer with PBS and remove the remaining PBS completely



Add 1ml Trizol (Invitrgen)/ 10 cm cell culture plate



Homogenize cells by pipetting up and down for a few times and transfer the cell
lysate to a fresh 1.5 ml tube



Isolate RNA according to the manufacture’s instruction



Resuspend RNA in diethyl pyrocarbonate (DEPC) treated water



Incubate in a water bath at 55°C for 10 min



Measure RNA concentration using an NanoDrop Spectrophotometer

(2) RT-PCR


Synthesize first-strand cDNA using SuperScript™ II RT (Invitrogen)



Set up a 20-µL reaction volume on ice using 1 µg total RNA as follows:



Random primers (500 ng/ml)

1 µl

dNTP mixture (10 mM each)

1 µl

RNA

1 µg

Sterile distilled H2O

To 13 µl

Heat the mixture to 65°C for 5 min and quick chill on ice. Collect the contents of the
tube by brief centrifugation and add:
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5x First-Strand Buffer

4 µl

0.1 M DTT

2 µl



Mix contents gently and incubate the mixture at RT for 2 min



Add 1 µl SuperScript™ II RT and mix by pipetting gently up and down



Perform RCP reactions on a thermocycler using the following PCR cycles:



25 °C

10 min

42 °C

50 min

70 °C

15 min

cDNA can be stored at 4 °C for a short period or at -80 °C for long term storage

(3) Realtime-PCR


Dilute cDNA by 1:50 in sterile distilled water



Set up a 25-µL reaction volume on ice using 10 µl diluted cDNA as follows:



Diluted cDNA

10 µl

Forward primer (10 µM)

0.5 µl

Reverse primer (10 µM)

0.5 µl

iQTM SYBR Green Supermix (BioRad)

12.5 µl

Sterile distilled water

1.5 µl

Perform RCP reactions on an iCycler (Bio-Rad) using the following PCR cycles:
Cycle 1 (1x)

95 °C

10 min

Cycle 2 (40x)

95 °C

30 sec

55 °C

30 sec

72 °C

30 sec

Cycle 3 (1x)

72 °C

10 min

Cycle 4 (1x)

10 °C

forever
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(4) Primers used for realtime-PCR in this study
Name

Sequence

human NOR1

F : 5’-GGGCTTTTTCAAGAGAACAGTG-3’
R: 5’-ATCTCTGGGTGTTGAGTCTGTT-3’

human VCAM-1

F: 5’-TGAGGGGACCAATTCCAC-3’
R: 5’-ATTCACGAGGCCACCACT-3’

human ICAM-1

F: 5’-ACCGTGAATGTGCTCTCC-3’
R: 5’-GGCTTGTGTGTTCGGTTT-3’

murine VCAM-1

F: 5’-TCAAAGAAAGGGAGACTG-3’
R: 5’-GCTGGAGAACTTCATTATC-3’

murine ICAM-1

F: 5’-AGATCACATTCACGGTGCTG-3’
R: 5’-CTTCAGAGGCAGGAAACAGG-3’

human TBP

F: 5’-GGAGAGTTCTGGGATTGTACCGC-3’
R: 5’-ATATTCGGCGTTTCGGGCAC-3’

murine TFIIB

F: 5’-CTCTCCCAAGAGTCACATGTCC-3’
R: 5’-CAATAACTCGGTCCCCTACAAC -3’

murine NOR1

F: 5’-GGCCGCAGCTGCACTCAGTC -3’
R: 5’-GCGGAGGGAAGGTCAGCGTG -3’

murine Nur77

F: 5’-TTGATGTTCCCGCCTTTG-3’
R: 5’-GGTAGCCATGTGCTCCTTC-3’

murine Nurr1

F: 5’-TCACCTCCGGTGAGTCTGATC-3’
R: 5’-TGCTGGATATGTTGGGTATCATCT-3’

rat NOR1

F: 5’-CAGCAGCTGCGAACTCAA-3’
R: 5’-CGGTGTAGAAGGCGGAGA-3’

rat RPL13A

F: 5’GTACGCTGTGAGGGCATCAA-3’
R: 5’-CTCGAGACGGGTTGGTGTTC-3’

rat HDAC1

F: 5’-CCATCAAAGGACATGCCAAGT-3’
R: 5’-CGAGCGACATTACGGATGGT-3’

rat HDAC2

F: 5’-CGGCAAGAAGAAAGTGTGCTACT-3’
R: 5’-ATGAGTCATCCGGATCCTATGG-3’

rat HDAC3

F: 5’-GCACCCGCATCGAGAATC-3’
R: 5’-TGGACACTGGGTGCATGGT-3’
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3. Immunostaining of OCT-embedded frozen sections


Heat slides in heated distilled water for 2 minutes and dry slides at RT



Fix tissues in chilled acetone at -20 °C for 1 min



Incubate in 0.5 % Triton X-100/ PBS at 40 °C for 10 min



Incubate in Redusol at 40 °C for 2 min



Incubate in automation buffer at RT for 1 min



Rinse slides with automation buffer 4 times at RT



Incubate in DAKO Blocking Reagent at 40 °C for 5 min



Rinse with automation buffer twice at RT



Dilute primary antibody in Dako Antibody Diluent (typically 1: 100 dilution)



Bind primary antibody at 40 °C for 15 min



Rinse slides with automation buffer 5 times at RT



Dilute biotinylated secondary antibody in Dako Antibody Diluent (typically 1: 200
dilution)



Bind secondary antibody at 40 °C for 15 min



Rinse with automation buffer 5 times at RT



Amplify antigen-antibody interaction using the Avidin-Biotin Complex (ABC)
(Vector Laboratories) at 40 °C for 10 min



Rinse with automation buffer 5 times at RT



Visualize signals by chromogen red 3-amino-9-ethylcarbazole (AEC) (Biomeda Corp)
at 40 °C for 10 min



Repeat the last step if necessary



Rinse slides with distilled water twice at RT



Flush slides with hematoxylin for nuclei visualization



Mount slides in glycerol with a coverglass
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4. Transient transfection assays
(1) Transient transfection of human endothelial cells using promofectin-HUVEC
(PromoKine)


Seed cells at 15x 104 / well in 6-well plates 24 hours before experiment



Dilute 4 µl promoter constructs (0.5 µg/ml) for each transfection in 25 µl
Opti-MEM® I Reduced Serum Medium (Opti-MEM) (Invitrogen), and mix well by
vortexing for 10 sec



Dilute 4 µl promofectin for each transfection in 25 µl Opti-MEM, and mix well by
vortexing for 10 sec



Mix DNA and promofectin dilutions and vortex the mixture for 10 sec



Incubate the mixture at RT for 20 min



While the mixture is incubating, wash the endothelial cells once with PBS and add 2
ml/ well fresh Opti-MEM



Add 50 µl/ well of the promofectin / DNA solution to the cells and shake the plate
gently



Incubate at 37 °C for 3 hours



Wash the cells three times with PBS and add 2 ml/ well fresh growth media

(2) Transient transfection of rat aortic smooth muscle cells using lipofectamine 2000
(Invitrogen)


Seed cells at 20x 104 / well in 6-well cell culture plates 24 hours before experiment



Dilute 4 µl promoter constructs (0.5 µg/ml) for each transfection in 250 µl
Opti-MEM, and mix well by vortexing for 10 sec



Dilute 6 µl lipofectamine 2000 for each transfection in 250 µl Opti-MEM, mix well
by vortexing for 10 sec and incubate at RT for 5 min



Mix DNA and lipofectamine 2000 dilutions and vortex the mixture for 10 sec



Incubate the mixture at RT for 20 min



While the mixture is incubating, add 2 ml/ well 5 % FBS DMEM without antibiotics
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Add the lipofectamine / DNA solution to the cells and shake the plate gently



Incubate at 37 °C for 7 hours



Wash the cells three times with PBS and add 2 ml/ well fresh growth media

5. Isolation of mouse aortic endothelial cells (MAEC)
(1) Cultrex® Basement Membrane Extract (BME) (R & D Systems)


Thaw BME at 2 – 8 °C on ice in a refrigerator overnight



Mix by slowly pipetting the solution up and down and be careful not to introduce air
bubbles



Pipette 50 μl/cm2 (500 μl/ 35 mm dish) onto the growth surface



Place coated object at 37 °C for 30 minutes and coated objects are ready for use

(2) Isolation of endothelial cells


Perfuse intracardially through the aorta using PBS and remove the ascending aorta



Remove adventitial tissue under a dissecting microscope



Cut the aorta into 3 µm long segments and rinse the segments with PBS



Place the segments on BME gel



Add 2 ml/ well of the endothelial cell growth media containing low-glucose DMEM
supplemented with 15 % FBS, 180 µg/ml heparin and 20 µg/ml endothelial cell
growth supplement



Change media every 2 days

(3) MAEC extraction and cell culture


Thaw Dispase in water bath and equilibrate to 37 °C



Remove medium from cell culture



Add 0.2 ml/cm2 Dispase to dish using sterile technique (e.g. 2 ml/ 35 mm dish, 6 ml/
60 mm dish, 16 ml/ 100 mm dish)



Incubate at 37 °C for 2 hours to insure complete dissolution of the gel



Pipette mixture up and down to disperse cell suspension



Transfer mixture to sterile centrifuge tube
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Stop action of Dispase by dilution or chelation of Ca++ and Mg++ using 5 - 10 mM
EDTA



Centrifuge cells at 1000 rpm, RT for 5 min and wash several times with PBS



Plate cells onto gelatin-coated dishes for 2 days in growth media containing D-valine
to eliminate possible fibroblast contamination



Return endothelial cells after 2 days to growth medium without D-valine and grow
cells to confluence



Test the purity of mouse endothelial cell cultures at passage 2 using either von
Willebrand Factor staining or di-acetylated LDL uptake



Perform subsequent passages with Trypsin-EDTA

6. Adhesion assay


Seed endothelial cells in the wells of a 6-well plate 24 hours before experiment



Maintain monocytes in suspension in 10 % FBS DMEM growth media



Fluorescently label monocytes (1x 107/ ml) in growth media containing 5 µg/ml
Calcein-AM at 37 °C for 30 min



Pellet cells by centrifugation at 1000 rpm, RT for 5 min



Wash cell three times with PBS



Resuspend fluorescently labeled monocytes in endothelial cell growth media at 1x
106 cells/ ml



Transfer 1 ml/ well monocyte dilutions onto endothelial cell monolayers



Bind at 37 °C for 30 min



Wash off unbound monocytes with PBS



Acquire images using fluorescent microscopy
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Appendix B. Additional data

Figure I. siRNA-mediated knock-down of NOR1 expression in endothelial cells
Western Blotting for NOR1 expression in endothelial cells transfected with scrambled or
NOR1 siRNA (50 nM) and treated with TNFα (1 ng/ml) for 6 h.
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Figure II. The purity of mouse aortic endothelial cells (MAEC) at passage 2
MAEC were cultured on coverglasses and immunostained for von Willebrand Factor (vWF)
and smooth muscle α-actin (α-SMA) to identify endothelial cells and smooth muscle cells.
Images were acquired using confocal microscopy (objective magnification x60). Stainings
for vWF, α-SMA and Hoechst were merged into one image as indicated. The purity of
MAEC at passage 2 was greater than 85 %.
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